<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83868</article-id><article-id pub-id-type="doi">10.7554/eLife.83868</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group></article-categories><title-group><article-title>Conformational regulation and target-myristoyl switch of calcineurin B homologous protein 3</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-301764"><name><surname>Becker</surname><given-names>Florian</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5889-8728</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-301765"><name><surname>Fuchs</surname><given-names>Simon</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-301766"><name><surname>Refisch</surname><given-names>Lukas</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9049-1944</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-301767"><name><surname>Drepper</surname><given-names>Friedel</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2043-5795</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-233873"><name><surname>Bildl</surname><given-names>Wolfgang</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-233874"><name><surname>Schulte</surname><given-names>Uwe</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3557-0591</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-301768"><name><surname>Liang</surname><given-names>Shuo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-301769"><name><surname>Heinicke</surname><given-names>Jonas Immanuel</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-301770"><name><surname>Hansen</surname><given-names>Sierra C</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-301771"><name><surname>Kreutz</surname><given-names>Clemens</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-160819"><name><surname>Warscheid</surname><given-names>Bettina</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5096-1975</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-45483"><name><surname>Fakler</surname><given-names>Bernd</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-310983"><name><surname>Mymrikov</surname><given-names>Evgeny V</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4817-6278</contrib-id><email>evgeny.mymrikov@biochemie.uni-freiburg.de</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-28410"><name><surname>Hunte</surname><given-names>Carola</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0826-3986</contrib-id><email>carola.hunte@biochemie.uni-freiburg.de</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0245cg223</institution-id><institution>Institute of Biochemistry and Molecular Biology, ZBMZ, Faculty of Medicine, University of Freiburg</institution></institution-wrap><addr-line><named-content content-type="city">Freiburg</named-content></addr-line><country>Germany</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0245cg223</institution-id><institution>Faculty of Biology, University of Freiburg</institution></institution-wrap><addr-line><named-content content-type="city">Freiburg</named-content></addr-line><country>Germany</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0245cg223</institution-id><institution>Institute of Medical Biometry and Statistics (IMBI), Faculty of Medicine and Medical Center, University of Freiburg</institution></institution-wrap><addr-line><named-content content-type="city">Freiburg</named-content></addr-line><country>Germany</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0245cg223</institution-id><institution>Institute of Physics, University of Freiburg</institution></institution-wrap><addr-line><named-content content-type="city">Freiburg</named-content></addr-line><country>Germany</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0245cg223</institution-id><institution>Biochemistry and Functional Proteomics, Institute of Biology II, Faculty of Biology, University of Freiburg</institution></institution-wrap><addr-line><named-content content-type="city">Freiburg</named-content></addr-line><country>Germany</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0245cg223</institution-id><institution>Institute of Physiology, Faculty of Medicine, University of Freiburg</institution></institution-wrap><addr-line><named-content content-type="city">Freiburg</named-content></addr-line><country>Germany</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0245cg223</institution-id><institution>CIBSS - Centre for Integrative Biological Signalling Studies, University of Freiburg</institution></institution-wrap><addr-line><named-content content-type="city">Freiburg</named-content></addr-line><country>Germany</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0245cg223</institution-id><institution>BIOSS Centre for Biological Signalling Studies, University of Freiburg</institution></institution-wrap><addr-line><named-content content-type="city">Freiburg</named-content></addr-line><country>Germany</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00fbnyb24</institution-id><institution>Department of Biochemistry, Theodor-Boveri-Institute, University of Würzburg</institution></institution-wrap><addr-line><named-content content-type="city">Würzburg</named-content></addr-line><country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Lemieux</surname><given-names>M Joanne</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0160cpw27</institution-id><institution>University of Alberta</institution></institution-wrap><country>Canada</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Swartz</surname><given-names>Kenton J</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id><institution>National Institute of Neurological Disorders and Stroke, National Institutes of Health</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>12</day><month>07</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e83868</elocation-id><history><date date-type="received" iso-8601-date="2022-09-30"><day>30</day><month>09</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-07-03"><day>03</day><month>07</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-09-23"><day>23</day><month>09</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.09.23.509142"/></event></pub-history><permissions><copyright-statement>© 2023, Becker, Fuchs et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Becker, Fuchs et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83868-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-83868-figures-v2.pdf"/><abstract><p>Calcineurin B homologous protein 3 (CHP3) is an EF-hand Ca<sup>2+</sup>-binding protein involved in regulation of cancerogenesis, cardiac hypertrophy, and neuronal development through interactions with sodium/proton exchangers (NHEs) and signalling proteins. While the importance of Ca<sup>2+</sup> binding and myristoylation for CHP3 function has been recognized, the underlying molecular mechanism remained elusive. In this study, we demonstrate that Ca<sup>2+</sup> binding and myristoylation independently affect the conformation and functions of human CHP3. Ca<sup>2+</sup> binding increased local flexibility and hydrophobicity of CHP3 indicative of an open conformation. The Ca<sup>2+</sup>-bound CHP3 exhibited a higher affinity for NHE1 and associated stronger with lipid membranes compared to the Mg<sup>2+</sup>-bound CHP3, which adopted a closed conformation. Myristoylation enhanced the local flexibility of CHP3 and decreased its affinity to NHE1 independently of the bound ion, but did not affect its binding to lipid membranes. The data exclude the proposed Ca<sup>2+</sup>-myristoyl switch for CHP3. Instead, a Ca<sup>2+</sup>-independent exposure of the myristoyl moiety is induced by binding of the target peptide to CHP3 enhancing its association to lipid membranes. We name this novel regulatory mechanism ‘target-myristoyl switch’. Collectively, the interplay of Ca<sup>2+</sup> binding, myristoylation, and target binding allows for a context-specific regulation of CHP3 functions.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>CHP3</kwd><kwd>NHE1</kwd><kwd>conformational changes</kwd><kwd>myristoylation</kwd><kwd>myristoyl switch</kwd><kwd>Ca<sup>2+</sup>-binding proteins</kwd><kwd>tescalcin</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>EXC-2189 - 390939984</award-id><principal-award-recipient><name><surname>Kreutz</surname><given-names>Clemens</given-names></name><name><surname>Warscheid</surname><given-names>Bettina</given-names></name><name><surname>Hunte</surname><given-names>Carola</given-names></name><name><surname>Fakler</surname><given-names>Bernd</given-names></name><name><surname>Mymrikov</surname><given-names>Evgeny V</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>SFB 1381 - 403222702</award-id><principal-award-recipient><name><surname>Schulte</surname><given-names>Uwe</given-names></name><name><surname>Hunte</surname><given-names>Carola</given-names></name><name><surname>Warscheid</surname><given-names>Bettina</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>SFB 1453 - 431984000</award-id><principal-award-recipient><name><surname>Fakler</surname><given-names>Bernd</given-names></name><name><surname>Hunte</surname><given-names>Carola</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>RTG 2202 - 278002225</award-id><principal-award-recipient><name><surname>Hunte</surname><given-names>Carola</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002347</institution-id><institution>Bundesministerium für Bildung und Forschung</institution></institution-wrap></funding-source><award-id>FKZ031L0080</award-id><principal-award-recipient><name><surname>Kreutz</surname><given-names>Clemens</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The target-myristoyl switch induced by protein-protein interaction is a novel regulatory mechanism for myristoylated EF-hand calcium-binding proteins, in which target binding facilitates exposure of the myristoyl anchor and the association to the lipid membrane in a calcium-independent manner.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The calcineurin B homologous protein 3 (CHP3, tescalcin) belongs to the EF-hand Ca<sup>2+</sup>-binding protein (EFCaBP) family (<xref ref-type="bibr" rid="bib35">Kolobynina et al., 2016</xref>) and is closely related to calcineurin B homologous proteins CHP1 and CHP2 (<xref ref-type="bibr" rid="bib12">Di Sole et al., 2012</xref>). CHPs interact with several isoforms of sodium/proton exchangers (NHEs), and this interaction is required for the localization and function of NHE transporters on the plasma membrane (<xref ref-type="bibr" rid="bib54">Pedersen and Counillon, 2019</xref>). Besides NHEs, CHP3 interacts with calcineurin A (<xref ref-type="bibr" rid="bib24">Gutierrez-Ford et al., 2003</xref>), subunit 4 of COP9 signalosome (<xref ref-type="bibr" rid="bib40">Levay and Slepak, 2014</xref>) and glycogen synthase kinase 3 (GSK3) (<xref ref-type="bibr" rid="bib33">Kobayashi et al., 2015</xref>). Recent studies revealed that the CHP3 expression level correlates with the progression, metastasis, and invasiveness of gastric, renal, and colorectal cancers (<xref ref-type="bibr" rid="bib29">Kang et al., 2016</xref>; <xref ref-type="bibr" rid="bib32">Kim et al., 2019</xref>; <xref ref-type="bibr" rid="bib39">Lee et al., 2018</xref>; <xref ref-type="bibr" rid="bib44">Luo et al., 2019</xref>). In addition, genome-wide association studies in combination with neuroimaging identified CHP3 as a key regulator of neurogenesis for hippocampal volume formation (<xref ref-type="bibr" rid="bib11">Dannlowski et al., 2015</xref>; <xref ref-type="bibr" rid="bib27">Horgusluoglu-Moloch et al., 2019</xref>; <xref ref-type="bibr" rid="bib61">Stein et al., 2012</xref>). Via regulation of GSK3 and calcineurin activities, it seems to counteract cardiac hypertrophy (<xref ref-type="bibr" rid="bib33">Kobayashi et al., 2015</xref>; <xref ref-type="bibr" rid="bib66">Viereck et al., 2020</xref>). Thus, CHP3 is an emerging important player in cellular Ca<sup>2+</sup> signalling networks involved in the regulation of cell proliferation and development in different tissues. The underlying molecular mechanisms are not well understood.</p><p>All three CHPs were shown to undergo conformational changes upon Ca<sup>2+</sup> binding (<xref ref-type="bibr" rid="bib24">Gutierrez-Ford et al., 2003</xref>; <xref ref-type="bibr" rid="bib42">Liang et al., 2020</xref>). Notably, CHP3 has a lower affinity for Ca<sup>2+</sup> (0.8 µM) (<xref ref-type="bibr" rid="bib24">Gutierrez-Ford et al., 2003</xref>) in comparison to CHP1 and CHP2 (<italic>K</italic><sub>D</sub> values below 100 nM) (<xref ref-type="bibr" rid="bib41">Li et al., 2011</xref>; <xref ref-type="bibr" rid="bib53">Pang et al., 2004</xref>). Further, Ca<sup>2+</sup>-binding affinities of CHP1 and CHP2 strongly increased (45- and 42-fold, respectively) upon binding of the NHE1 target peptide (<xref ref-type="bibr" rid="bib41">Li et al., 2011</xref>; <xref ref-type="bibr" rid="bib53">Pang et al., 2004</xref>). This modulation is a common feature in EFCaBPs (<xref ref-type="bibr" rid="bib19">Gifford et al., 2007</xref>) and should also apply to the CHP3 isoform. CHP3 may thus respond to Ca<sup>2+</sup> signals with conformational changes when the intracellular Ca<sup>2+</sup> concentration elevates from 100 nM to 1 µM or higher (<xref ref-type="bibr" rid="bib57">Roderick and Cook, 2008</xref>). Ca<sup>2+</sup>-induced conformational changes are characteristic for Ca<sup>2+</sup> sensor proteins such as calmodulin (CaM) and calcineurin B (<xref ref-type="bibr" rid="bib10">Creamer, 2020</xref>; <xref ref-type="bibr" rid="bib49">Nelson and Chazin, 1998</xref>). At the resting Ca<sup>2+</sup> level, they adopt a closed conformation, in which the hydrophobic target-binding pocket is occluded. Upon a rise of the intracellular Ca<sup>2+</sup> concentration, Ca<sup>2+</sup> binding to EF-hand(s) causes an opening of this pocket providing the structural basis for the transmission of Ca<sup>2+</sup> signals (<xref ref-type="bibr" rid="bib49">Nelson and Chazin, 1998</xref>). This opening often triggers the binding of EFCaBPs to their target proteins (<xref ref-type="bibr" rid="bib8">Burgoyne et al., 2019</xref>). In addition, Ca<sup>2+</sup>-induced conformational changes of EFCaBPs such as calcineurin B or guanylyl cyclase activating proteins (GCAPs) stably associated with target proteins can affect the function of the latter (<xref ref-type="bibr" rid="bib10">Creamer, 2020</xref>; <xref ref-type="bibr" rid="bib43">Lim et al., 2014</xref>). Recently, we demonstrated an increase of CHP3 hydrophobicity upon Ca<sup>2+</sup> binding that most likely resulted from the opening of the hydrophobic target-binding pocket (<xref ref-type="bibr" rid="bib42">Liang et al., 2020</xref>). CHP3 binds also Mg<sup>2+</sup> with a low affinity (<italic>K</italic><sub>D</sub> = 73 µM) in the absence of Ca<sup>2+</sup>. The presence of 1 mM Mg<sup>2+</sup> reduces the affinity for Ca<sup>2+</sup> from 0.8 to 3.5 µM, indicating a direct competition between Ca<sup>2+</sup> and Mg<sup>2+</sup> for the EF-3 binding site (<xref ref-type="bibr" rid="bib24">Gutierrez-Ford et al., 2003</xref>). Thus, CHP3 should be present in the Mg<sup>2+</sup>-bound state in a cell at basal Ca<sup>2+</sup> concentration, ready to respond to Ca<sup>2+</sup> signals, yet, the exact mechanism is not fully described.</p><p>In addition, CHP3 harbors an N-terminal myristoylation site similar to other EFCaBPs such as recoverin and calcineurin B (<xref ref-type="bibr" rid="bib24">Gutierrez-Ford et al., 2003</xref>; <xref ref-type="bibr" rid="bib72">Zaun et al., 2012</xref>). This modification often enhances protein binding to cellular membranes, but it can also stabilize the structure of a protein and/or regulate its function (<xref ref-type="bibr" rid="bib71">Yuan et al., 2020</xref>; <xref ref-type="bibr" rid="bib28">Jiang et al., 2018</xref>). Membrane binding via the myristoyl moiety is usually enforced with either a second lipidation site or clusters of positively charged and/or hydrophobic residues (<xref ref-type="bibr" rid="bib71">Yuan et al., 2020</xref>; <xref ref-type="bibr" rid="bib28">Jiang et al., 2018</xref>). The exposure of the myristoyl moiety from the modified protein and thereby its binding to lipid membranes can be regulated by various signals, for instance by exchange of GDP to GTP (GTP-myristoyl switch in ADP ribosylation factor 1 [ARF1] GTPase) (<xref ref-type="bibr" rid="bib22">Goldberg, 1998</xref>), by phosphorylation (myristoyl/phosphoserine switch in myristoylated alanine-rich C kinase substrate (MARCKS) [<xref ref-type="bibr" rid="bib5">Braun et al., 2000</xref>] and in the C-subunit of protein kinase A [<xref ref-type="bibr" rid="bib18">Gaffarogullari et al., 2011</xref>]) or by pH change (pH-dependent myristoyl-histidine switch in hisactophilin [<xref ref-type="bibr" rid="bib26">Hanakam et al., 1996</xref>]). In many Ca<sup>2+</sup> sensor proteins (for instance recoverin, neurocalcin, visinin-like proteins), the myristoyl group becomes accessible to lipid membranes after Ca<sup>2+</sup> binding (<xref ref-type="bibr" rid="bib43">Lim et al., 2014</xref>). This mechanism is called Ca<sup>2+</sup>-myristoyl switch. However, not all myristoylated EFCaBPs have a Ca<sup>2+</sup>-myristoyl switch. In the neuronal calcium sensor-1 (NCS-1) and in KChIP1, the myristoyl moiety becomes exposed in the presence of lipid membranes even at low Ca<sup>2+</sup> concentration (<xref ref-type="bibr" rid="bib43">Lim et al., 2014</xref>; <xref ref-type="bibr" rid="bib46">McFerran et al., 1999</xref>; <xref ref-type="bibr" rid="bib52">O’Callaghan and Burgoyne, 2004</xref>; <xref ref-type="bibr" rid="bib51">O’Callaghan et al., 2003</xref>); and it is constantly hidden within the protein core in GCAPs (<xref ref-type="bibr" rid="bib43">Lim et al., 2014</xref>).</p><p>Myristoylated CHP1 binds to microsomal membranes in a Ca<sup>2+</sup>-dependent manner indicating the presence of a Ca<sup>2+</sup>-myristoyl switch (<xref ref-type="bibr" rid="bib3">Andrade et al., 2004</xref>), whereas binding of myristoylated CHP3 to lipid membranes has not been reported so far. Co-expression of NHE1 with CHP3 that lacks myristoylation and/or Ca<sup>2+</sup>-binding sites significantly reduced the half-life at the cell surface and the activity of this transporter (<xref ref-type="bibr" rid="bib72">Zaun et al., 2012</xref>). Simultaneous myristoylation and Ca<sup>2+</sup> binding was suggested to be important for NHE1 stabilization by CHP3 (<xref ref-type="bibr" rid="bib72">Zaun et al., 2012</xref>). Based on these results, the presence of a Ca<sup>2+</sup>-myristoyl switch for CHP3 was proposed (<xref ref-type="bibr" rid="bib24">Gutierrez-Ford et al., 2003</xref>; <xref ref-type="bibr" rid="bib72">Zaun et al., 2012</xref>), though the exposure of the myristoyl group in response to Ca<sup>2+</sup> binding has not been shown experimentally.</p><p>The interaction of CHP3 with NHE1 is an ideal system to analyse the effects of myristoylation and Ca<sup>2+</sup> binding on CHP3. We previously demonstrated that CHP3 binds at 1:1 ratio to the CHP-binding region of human NHE1 (CBD) with high affinity in the presence of Mg<sup>2+</sup> (<xref ref-type="bibr" rid="bib17">Fuchs et al., 2018</xref>). At the same time, it was shown by co-immunoprecipitation of CHP3-myc and NHE1-HA that addition of Ca<sup>2+</sup> increased the amount of the complex formed (<xref ref-type="bibr" rid="bib72">Zaun et al., 2012</xref>). Here, we show that Ca<sup>2+</sup> and N-terminal myristoylation independently regulate the conformation of CHP3 and its interaction with NHE1 providing the molecular basis for regulation of CHP3 function. This excludes a Ca<sup>2+</sup>-myristoyl switch in CHP3, instead, surface exposure of the myristoyl moiety was triggered by target peptide binding as probed by interaction with liposomes. We named this novel mechanism ‘target-myristoyl switch’. Our study provides fundamental mechanistic understanding of the regulation of CHP3 function.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Pure fully myristoylated and non-myristoylated untagged CHP3 are functional in binding a single calcium ion</title><p>In order to dissect the effects of Ca<sup>2+</sup> and myristoylation on target and lipid binding of human CHP3, we aimed for pure untagged CHP3 and myristoylated CHP3 (mCHP3). Non-myristoylated CHPs were previously produced with affinity tags and purified by corresponding affinity chromatography (<xref ref-type="bibr" rid="bib24">Gutierrez-Ford et al., 2003</xref>; <xref ref-type="bibr" rid="bib42">Liang et al., 2020</xref>; <xref ref-type="bibr" rid="bib17">Fuchs et al., 2018</xref>). Yet, the peptide tag used for affinity purification of rat CHP1 was shown to interact with the hydrophobic target-binding pocket (<xref ref-type="bibr" rid="bib48">Naoe et al., 2005</xref>) and might interfere with conformational changes. Myristoylated untagged CHP1 had been produced with low yield by co-expression with yeast N-myristoyltransferase (<xref ref-type="bibr" rid="bib64">Timm et al., 1999</xref>). Here, we produced untagged CHP3 and mCHP3, the latter by co-expression with human N-myristoyltransferase 1, and used Ca<sup>2+</sup>-dependent hydrophobic interaction chromatography (HIC) for purification. HIC has been previously used for purification of other EFCaBPs including CaM and calcineurin B (<xref ref-type="bibr" rid="bib62">Tanaka et al., 1984</xref>; <xref ref-type="bibr" rid="bib69">Wei and Lee, 1997</xref>). Combining HIC and gel filtration, we obtained pure untagged proteins, as shown by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) analysis (<xref ref-type="fig" rid="fig1">Figure 1A</xref>) with an average yield of 9 mg/l of expression culture. Single symmetrical peaks in the elution profiles of analytical gel filtration indicated monodisperse protein preparations of CHP3 and mCHP3. Both proteins form only monomers under reducing conditions in the presence of 2 mM TCEP (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). The slightly higher electrophoretic mobility of mCHP3 compared to CHP3 resolved in high-resolution SDS–PAGE analysis already indicated that the protein was covalently modified (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). To check the degree of myristoylation, we analysed mCHP3 and CHP3 by native mass spectrometry (MS). The measured mass of mCHP3 was increased by ~211 Da (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, bottom) in comparison to CHP3 (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, top), which is in agreement with the covalent attachment of one myristoyl group (<italic>M</italic><sub>r</sub> = 210 Da). Native MS analysis of three independently produced and purified samples confirmed reproducible complete myristoylation of recombinant CHP3. Interestingly, the ion mobility arrival time was shorter for mCHP3 (<xref ref-type="fig" rid="fig1">Figure 1C</xref>) indicating a more compact shape of mCHP3 compared to CHP3. To reveal the stoichiometry of Ca<sup>2+</sup> binding, we performed native MS analysis of CHP3 and mCHP3 after addition of Ca<sup>2+</sup>. The molecular masses of both proteins were shifted by ~40 Da (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), which corresponds to the binding of a single Ca<sup>2+</sup> ion and, thus, documents that both recombinant CHP3 and mCHP3 are functional in respect to Ca<sup>2+</sup> binding and confirms the presence of one Ca<sup>2+</sup>-binding site (<xref ref-type="bibr" rid="bib24">Gutierrez-Ford et al., 2003</xref>; <xref ref-type="bibr" rid="bib55">Perera et al., 2001</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Quality control of the purified non-myristoylated CHP3 and myristoylated CHP3 (mCHP3).</title><p>(<bold>A</bold>) Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) analysis (16%, tricine mini gels) showed a mobility shift of mCHP3 in comparison to CHP3; positions of co-migrated molecular mass standards are indicated in kDa on the left; <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>: Full gel for (A). (<bold>B</bold>) Left, deconvoluted mass spectra of CHP3 (top) and mCHP3 (bottom) show a measured intact protein mass of 24.617 and 24.828 kDa (∆<italic>M</italic><sub>r</sub> = 211 Da), which is in line with the addition of the myristoyl group of 210 Da. For mCHP3, also low abundant dimeric species were observed by native MS analysis. Right, zoom-in spectra in the range of 24.8 ± 0.3 kDa that show differences in masses as indicated by dashed lines. In the presence of Ca<sup>2+</sup>, the measured intact protein mass of CHP3 and mCHP3 was increased by ~40 Da (mass accuracy ± 1 Da), respectively, indicating binding of one Ca<sup>2+</sup> ion. (<bold>C</bold>) Ion mobility arrival time distributions for the +8 charge state of CHP3 (solid line) and mCHP3 (dashed line). A shoulder with shorter arrival times indicates the presence of a low abundant dimeric species for CHP3 and mCHP3. Arrival times of mCHP3 were reduced by 1.36 ms (±0.37 ms; <italic>n</italic> = 3; p = 0.024) compared to CHP3. See <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref> for non-deconvoluted mass spectra showing charge state distributions of CHP3 and mCHP3 measured in the positive ion mode by native MS.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Full gel for <xref ref-type="fig" rid="fig1">Figure 1A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83868-fig1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83868-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Analytical size exclusion chromatography of purified CHP3 (<bold>A</bold>) and mCHP3 (<bold>B</bold>) on Superdex 75 Increase 10/300 GL.</title><p>The position of elution peaks of mass standards (aldolase: 158 kDa, conalbumin: 75 kDa, carbonic anhydrase: 29 kDa, cytochrome c: 12.4 kDa) are indicated on the top.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83868-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Non-deconvoluted mass spectra showing charge state distributions of CHP3 and mCHP3 measured in the positive ion mode by native MS.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83868-fig1-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Ca<sup>2+</sup>-induced conformational changes are similar in CHP3 and mCHP3</title><p>Next, we analysed the effect of Ca<sup>2+</sup> binding in the presence of Mg<sup>2+</sup> and of the N-terminal myristoylation on CHP3 conformation. For this purpose, we optimized the FPH (fluorescence probe hydrophobicity) assay, previously developed to monitor Ca<sup>2+</sup>-induced conformational changes of CHPs (<xref ref-type="bibr" rid="bib42">Liang et al., 2020</xref>), by using the dye ProteOrange (Lumiprobe) at defined micromolar concentration (see Materials and methods). In this assay, the fluorescence of the dye strongly increases upon its binding to hydrophobic protein surfaces (<xref ref-type="bibr" rid="bib50">Niesen et al., 2007</xref>).</p><p>In the Mg<sup>2+</sup>-bound state, CHP3 and mCHP3 showed low fluorescence (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). After Ca<sup>2+</sup> addition, the fluorescence intensity increased by 30% and 40% for CHP3 and mCHP3, respectively, reflecting an increase in hydrophobicity (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Ca<sup>2+</sup> removal by EGTA reduced the fluorescence to the initial level, indicating the reversibility of Ca<sup>2+</sup> binding and of the respective conformational changes. Depletion of both Mg<sup>2+</sup> and Ca<sup>2+</sup> by EDTA turned the protein into the non-physiological apo-state, the fluorescence was in between that of the Mg<sup>2+</sup>- and Ca<sup>2+</sup>-bound states. The proteins appeared to be destabilized in the apo-state and could not be reverted into the functional form by Ca<sup>2+</sup> addition (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Interestingly, the N-terminal myristoylation did not affect the conformational changes of CHP3. As a control, we probed the hydrophobicity of recoverin, the prototypic protein with a classical Ca<sup>2+</sup>-myristoyl switch (<xref ref-type="bibr" rid="bib1">Ames et al., 1997</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). Ca<sup>2+</sup> induced similar changes of non-myristoylated recoverin as of CHP3 in the FPH assay, whereas hydrophobicity of the myristoylated protein increased much stronger (about 3.5-fold) in response to Ca<sup>2+</sup> binding, which most likely resulted from the exposure of the myristic group.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Ca<sup>2+</sup>-induced conformational changes in CHP3 and mCHP3.</title><p>(<bold>A</bold>) Kinetic fluorescence probe hydrophobicity (FPH) assay. Fluorescence of dye bound at hydrophobic protein surfaces was monitored at <italic>λ</italic><sub>em</sub> = 585 nm (excitation <italic>λ</italic><sub>ex</sub> = 470 nm) and at 22°C. Protein (1.5 µM) was prepared in the Mg<sup>2+</sup>-bound state (2 mM MgCl<sub>2</sub>, 1 mM EGTA). CaCl<sub>2</sub>, EDTA, and EGTA were sequentially added as indicated. First, 2 mM CaCl<sub>2</sub> was added and then chelated with addition of 3 mM EGTA. Next, 3 mM EDTA was added to remove both divalent ions (CHP3 in apo-state) followed by another addition of 4 mM CaCl<sub>2</sub>. (<bold>B</bold>) Intrinsic tryptophan fluorescence was monitored at <italic>λ</italic><sub>em</sub> = 330 nm (excitation <italic>λ</italic><sub>ex</sub> = 280 nm) at 22°C. Protein (2.5 μM) in the Mg<sup>2+</sup>-bound state was used and the additions were performed as described above for the FPH assay. (<bold>C</bold>) AlphaFold2.0 model (<xref ref-type="bibr" rid="bib65">Varadi et al., 2022</xref>) of CHP3 in surface presentation, with surface coloured for hydrophobicity (<xref ref-type="bibr" rid="bib15">Eisenberg et al., 1984</xref>). The model most likely resembles the open or target-bound conformation. The single tryptophan residue highlighted in green (Trp191) is located in the hydrophobic target-binding pocket. EC50 values for binding of Ca<sup>2+</sup> to CHP3 (<bold>D</bold>) and mCHP3 (<bold>E</bold>) determined with FPH assay. Fluorescence of samples with CHP3 or mCHP3 at different Ca<sup>2+</sup> concentrations was measured at 590 nm in the presence of 2 mM MgCl<sub>2</sub>. Three biological replicates (shown in different colours) with three to four technical replicates each for CHP3 and mCHP3 were measured. The data were fitted with Hill equation using global non-linear regression. (<bold>F</bold>) 95% confidence intervals (Δ<italic>χ</italic><sup>2</sup> of 3.84) of EC50 values for binding of Ca<sup>2+</sup> calculated with profile likelihood method. EC50 values (asterisks) are shown with confidence intervals in square brackets below the graph.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83868-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Conformational changes of CHP3, mCHP3, recoverin, and myristoylated recoverin monitored with the fluorescence probe hydrophobicity (FPH) assay.</title><p>(<bold>A</bold>) Original fluorescence traces of the FPH assay for three biological replicates of CHP3 and mCHP3. (<bold>B</bold>) Normalized fluorescence traces of the FPH assay for myristoylated and non-myristoylated recoverin (mRec and Rec).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83868-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Intrinsic tryptophan fluorescence spectra of CHP3 (<bold>A</bold>) and mCHP3 (<bold>B</bold>).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83868-fig2-figsupp2-v2.tif"/></fig></fig-group><p>To prove that changes in the dye-mediated fluorescence observed in the FPH assay were indeed caused by conformational changes, we probed the intrinsic tryptophan fluorescence of CHP3 and mCHP3. According to the 3D model of CHP3 predicted with AlphaFold2.0 (<xref ref-type="bibr" rid="bib65">Varadi et al., 2022</xref>), the single tryptophan residue (Trp191) is located in CHP3’s hydrophobic target-binding pocket at the protein surface (<xref ref-type="fig" rid="fig2">Figure 2C</xref>) in line with the measured emission maxima of CHP3 and mCHP3 of ~330 nm (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). Intensity and emission maximum of intrinsic tryptophan fluorescence depend on the local environment of the residue (<xref ref-type="bibr" rid="bib67">Vivian and Callis, 2001</xref>; <xref ref-type="bibr" rid="bib14">Eftink, 2000</xref>). Ca<sup>2+</sup> addition decreased the intrinsic fluorescence of CHP3 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>) reflecting conformational changes accompanied with changes in the local environment of Trp191 in the hydrophobic pocket. This is in line with an increase of CHP3 hydrophobicity observed with the FPH assay. These conformational changes monitored by intrinsic fluorescence were also reverted by Ca<sup>2+</sup> removal (EGTA addition) (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Only for mCHP3, the removal of both Mg<sup>2+</sup> and Ca<sup>2+</sup> caused irreversible changes in the intrinsic fluorescence.</p><p>In order to evaluate whether myristoylation affects the Ca<sup>2+</sup>-binding affinity of CHP3, we determined the EC50 values for binding of Ca<sup>2+</sup> to CHP3 and mCHP3 in the presence of Mg<sup>2+</sup> using the FPH assay. Addition of Ca<sup>2+</sup> at saturating concentration increased the fluorescence (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). We now titrated Ca<sup>2+</sup> concentration from 0.3 µM to 8 mM and measured fluorescence using biological and technical replicates (<xref ref-type="fig" rid="fig2">Figure 2D, E</xref>). We determined Ca<sup>2+</sup> EC50 values performing a global fit for all data. The difference between EC50’s obtained for CHP3 (161.1 [112.6; 233.8] μM; <xref ref-type="fig" rid="fig2">Figure 2D</xref>) and mCHP3 (152.6 [113.7; 209.7] µM; <xref ref-type="fig" rid="fig2">Figure 2E</xref>) is insignificant, indicating that myristoylation does not affect the Ca<sup>2+</sup>-binding properties of CHP3.</p><p>Combining the data of the FPH assay and of the intrinsic tryptophan fluorescence, we conclude that CHP3 undergoes reversible Ca<sup>2+</sup>-induced conformational changes as typical for a Ca<sup>2+</sup> sensor protein. The hydrophobic target-binding pocket of CHP3 is occluded in the Mg<sup>2+</sup>-bound state (closed conformation), and becomes exposed to the environment upon Ca<sup>2+</sup> binding (open conformation).</p></sec><sec id="s2-3"><title>Ca<sup>2+</sup> binding and myristoylation independently affect thermal stabilities of CHP3 and its complex with NHE1 target peptide</title><p>To further dissect the effects of Ca<sup>2+</sup> and N-terminal myristoylation on CHP3, we probed the thermal stability of CHP3 alone and in complex with the CHP-binding domain of NHE1 (CBD, NHE1 residues 525–545) using nano-differential scanning fluorimetry (nanoDSF). To obtain the CHP3:CBD complex used for nanoDSF, we co-expressed CHP3 and CBDHis using the pETDuet-1 system and purified the resulting complex. For the myristoylated complex (mCHP3:CBD), simultaneous co-expression of three proteins (CHP3, CBDHis, and human <italic>N</italic>-myristoyltransferase 1 (NMT1)) from a modified pETDuet-1 vector was performed, and the resulting complex was purified. Myristoylation of CHP3 in the complex was confirmed by electrospray ionization (ESI)-TOF mass spectrometric analysis. Free CHP3 had the highest thermal stability in the Mg<sup>2+</sup>-bound state (<italic>T</italic><sub>m</sub><sup>app</sup> 70.1 ± 0.3°C), and Ca<sup>2+</sup> binding reduced the melting point to 66.9 ± 0.2°C (CHP3 in <xref ref-type="fig" rid="fig3">Figure 3</xref>). In the presence of both ions, the Ca<sup>2+</sup> effect appeared to be dominant with a melting temperature (<italic>T</italic><sub>m</sub><sup>app</sup>) of 65.0 ± 0.9°C. In line with the results of the FPH assay, which indicated a destabilized apo-state, the latter showed strongly reduced thermal stability (<italic>T</italic><sub>m</sub><sup>app</sup> 56.1 ± 0.5°C). Notably, binding of the target peptide CBD strongly increased the thermal stability for the Ca<sup>2+</sup>-bound and apo-states (compare CHP3 and CHP3:CBD in <xref ref-type="fig" rid="fig3">Figure 3</xref>), with about 12°C in the presence of Ca<sup>2+</sup>, 13°C in the presence of Ca<sup>2+</sup> plus Mg<sup>2+</sup> and about 11°C for the apo-state. Thus, the CHP3:CBD complex showed the highest thermal stability when Ca<sup>2+</sup> was bound. Surprisingly, CBD binding did not have any effect on the thermal stability of the Mg<sup>2+</sup>-bound state.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Ca<sup>2+</sup> and target peptide binding affect the thermal stability of CHP3 and mCHP3.</title><p>Thermal stabilities of free proteins and complexes with the target peptide CBD were measured with nanoDSF in the presence of either 10 mM Mg<sup>2+</sup>, Ca<sup>2+</sup>, Ca<sup>2+</sup> + Mg<sup>2+</sup>, or EDTA. Temperatures of thermal unfolding (apparent <italic>T</italic><sub>m</sub>) are shown as mean ± standard deviation (SD) of three independent biological replicates. Raw nanoDSF traces are shown in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83868-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Thermal unfolding of CHP3 (<bold>A</bold>), mCHP3 (<bold>B</bold>), CHP3:CBD (<bold>C</bold>), and mCHP3:CBD (<bold>D</bold>) shown as raw nanoDSF traces (left) and first derivatives (right) in the presence of either Mg<sup>2+</sup>, Ca<sup>2+</sup>, Mg<sup>2+</sup> + Ca<sup>2+</sup>, or in the absence of both ions (EDTA).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83868-fig3-figsupp1-v2.tif"/></fig></fig-group><p>The N-terminal myristoylation decreased the <italic>T</italic><sub>m</sub><sup>app</sup> of CHP3 in all states to the same degree (9.8°C for Mg<sup>2+</sup>-bound and 10.6°C for Ca<sup>2+</sup>-bound states, 10.9°C in the presence of both ions, 4.5°C for the already destabilized apo-state) (compare CHP3 and mCHP3 in <xref ref-type="fig" rid="fig3">Figure 3</xref>). A similar destabilizing effect of the myristoylation was observed for the mCHP3:CBD complex with a decrease of <italic>T</italic><sub>m</sub><sup>app</sup> in the range from 6.4°C for the Ca<sup>2+</sup>-bound state to 3.2°C for the apo-state (compare CHP3:CBD and mCHP3:CBD in <xref ref-type="fig" rid="fig3">Figure 3</xref>). Thus, the N-terminal myristoylation lowers the stability of CHP3 independently of the bound ion and of the target binding that means independent of the conformation.</p></sec><sec id="s2-4"><title>Ca<sup>2+</sup> binding to CHP3 allows more effective cleavage within EF-2, whereas CBD binding drastically increases proteolytic stability</title><p>In order to pinpoint flexible regions of CHP3 in a given conformation and to probe whether these regions are affected by myristoylation, ion and target binding, we performed limited trypsinolysis of CHP3, mCHP3, and their complexes with CBD in the presence of Ca<sup>2+</sup>, Mg<sup>2+</sup>, or EDTA.</p><p>CHP3 was readily proteolysed by trypsin with nearly one half of the protein already degraded after 5 min and almost no full-length protein remained after 60-min incubation (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, top, FL). Trypsin cleavage sites (Arg and Lys residues) are distributed all over the CHP3 amino acid sequence (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>), yet productive cleavage requires not only availability of the site but also flexibility of the peptide chain at the cleavage site to adapt to the active site of the protease (<xref ref-type="bibr" rid="bib63">Teilum et al., 2009</xref>). During the reaction, we observed the appearance of two major fragments (labelled 1 and 2 in <xref ref-type="fig" rid="fig4">Figure 4A</xref>). We analysed those fragments with MS to determine exact masses and precisely locate the cleavage sites (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). Fragment 1 has a mass of 17.92 kDa corresponding to residues 2–155 of CHP3 (UniProtID Q96BS2-1) lacking the C-terminal part (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Fragment 2 has a mass of 9.63 kDa and includes residues 74–155. Thus, it derived from a cleavage of fragment 1 within the predicted EF-2 (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Noteworthy, both fragments still contain the single functional EF<bold>-</bold>hand of CHP3 (EF-3). Target peptide binding nearly completely prevented the trypsin cleavage, and the intensity of the full-length CHP3 band was only slightly reduced even after 60-min incubation (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, bottom). Next, we compared the proteolytic stability of CHP3 in different states. In the presence of only Ca<sup>2+</sup>, Mg<sup>2+</sup>, or both ions together, the degradation rate of the full-length protein (FL) was comparable, whereas the apo-state degraded much faster (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, FL). Fragment 1 appeared already after 5 min and degraded further over time (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, 1), its cleavage was more pronounced in the presence of Ca<sup>2+</sup> and was accompanied with an increase of fragment 2 (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, 2). This indicates that the cleavage site located in EF-2 becomes more available for the protease in the open conformation (Ca<sup>2+</sup> bound). N-terminal myristoylation did not affect the proteolytic stability of the full-length protein, whereas it slightly reduced the stability of fragment 1 in all states. In addition, a second minor band below fragment 1 appeared for mCHP3 (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). The small differences in the tryptic cleavage of CHP3 and mCHP3 indicate a local destabilizing effect of the myristoyl moiety, in line with the lower thermal stability of mCHP3 compared to CHP3. The complex formation with CBD drastically increased the proteolytic stability of both CHP3 and mCHP3, as nearly no degradation occurred under all analysed experimental conditions (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, CHP3:CBD and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Ca<sup>2+</sup>-binding and complex formation change the accessibility of trypsin cleavage sites in CHP3 and mCHP3.</title><p>(<bold>A</bold>) Time-dependent (0–60 min) limited proteolysis (trypsin) of CHP3 (top) and the complex of CHP3:CBD (bottom) in the presence of both Mg<sup>2+</sup> and Ca<sup>2+</sup>. Positions of full-length protein (FL) and two major proteolytic fragments (1 and 2) as well as CBD are indicated on the right of the Coomassie-stained SDS–PAGE gel, positions of co-separated molecular mass standards (mass in kDa) – on the left; the sample containing only trypsin was loaded on the first lane (T); <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>: Full gels of (A). (<bold>B</bold>) Time-dependent limited proteolysis of CHP3 and mCHP3 in the presence of Mg<sup>2+</sup>, Ca<sup>2+</sup>, both ions or in the absence of them. Sections of the gel with bands corresponding to the full-length protein (FL) and two major proteolytic fragments (1 and 2) are shown. Nearly no degradation was observed for CHP3 and mCHP3 in the complex with CBD in all conditions (Mg<sup>2+</sup> + Ca<sup>2+</sup> condition is presented here, other gels are shown in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref> and its source data). (<bold>C</bold>) Schematic representation of full-length CHP3 with indication of N- and C-lobes, four EF-hand motifs (active EF-3 is highlighted in green). Proteolytic fragments 1 and 2 and trypsin cleavage sites were identified by mass spectrometry. (<bold>D</bold>) Combined ribbon and surface presentation of the CHP3 AlphaFold2.0 model (<xref ref-type="bibr" rid="bib65">Varadi et al., 2022</xref>) with N- and C-lobes shown in blue and orange, respectively, and the connecting CHP-loop in cyan; the two major trypsin cleavage sites are highlighted in yellow and Ca<sup>2+</sup> ion as a green sphere. The Ca<sup>2+</sup> position in EF-3 was modelled by superimposition of the CHP3 model with the CHP1 X-ray structure, pdb ID 2ct9 (<xref ref-type="bibr" rid="bib3">Andrade et al., 2004</xref>).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Full gels for <xref ref-type="fig" rid="fig4">Figure 4A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83868-fig4-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83868-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Limited trypsinolysis of CHP3 and mCHP3.</title><p>(<bold>A</bold>) Location of potential trypsin cleavage sites (Lys and Arg residues) in the CHP3 sequence. The two major sites, at which the cleavage is effective in the limited proteolysis are highlighted in red. (<bold>B</bold>) The full-size gels of limited proteolysis in different conditions. Proteins samples are indicated on the left, the ion conditions – on the top, trypsin only (T), or different CHP3 samples (CHP3, mCHP3, CHP3:CBD, or mCHP3:CBD) incubated with trypsin for 0, 5, 15, 30, 45, and 60 min were loaded from the left to the right. For a band annotation, see <xref ref-type="fig" rid="fig4">Figure 4A</xref>. Gels of CHP3 (MgCl<sub>2</sub>+CaCl<sub>2</sub>) and of CHP3:CBD (MgCl<sub>2</sub>+CaCl<sub>2</sub>) from <xref ref-type="fig" rid="fig4">Figure 4A</xref> (<bold>C</bold>) LC–ESI-TOF mass spectrometry analysis of major proteolytic fragments (1 and 2), the detected masses were 17,922 Da for the fragment 1 and 9630 Da for the fragment 2.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Full gels for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83868-fig4-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83868-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Multiple sequence alignment of human CHP1, CHP2, and CHP3.</title><p>CHP3 has one active EF-hand only, which is EF-3 (green box). EF-2 and EF-4 of CHP3 have 9-residue insertions, which disrupt the canonical Ca<sup>2+</sup>-coordinating loop, whereas EF-1 of CHP3 lacks the conservative negatively charged residues important for Ca<sup>2+</sup> coordination (positions X, Y and –Z, respective CHP3 residues are S36, G37, and N46). EF-1, EF-2, and EF-4 that do not bind Ca<sup>2+</sup> in CHP3 are shown in red rectangles. N-terminal myristoylation site is indicated with an arrow. Sequence alignment was done in BioEdit (<xref ref-type="bibr" rid="bib25">Hall, 1999</xref>) using ClustalW algorithm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83868-fig4-figsupp2-v2.tif"/></fig></fig-group><p>We mapped both major cleavage sites on the 3D model of CHP3 predicted with AlphaFold2.0 (<xref ref-type="bibr" rid="bib65">Varadi et al., 2022</xref>; <xref ref-type="fig" rid="fig4">Figure 4D</xref>). This model closely resembles the structures of CHP1 and CHP2 in complex with CBD (<xref ref-type="bibr" rid="bib2">Ammar et al., 2006</xref>; <xref ref-type="bibr" rid="bib47">Mishima et al., 2007</xref>), of CHP1 in complex with full-length NHE1 (<xref ref-type="bibr" rid="bib13">Dong et al., 2021</xref>) and of CHP1 with an artificial C-terminal helix bound in the target-binding pocket (<xref ref-type="bibr" rid="bib31">Kennedy et al., 1996</xref>), that is structures of target-bound CHPs. All these structures represent the Ca<sup>2+</sup>-bound state. The cleavage site R155/S156 is located in this model at the N-side of the incoming α-helix of EF-4 and though surface exposed the α-helical location may hamper the proteolytic digest (<xref ref-type="bibr" rid="bib16">Fontana et al., 1997</xref>). The other site, R73/K74 is located in the middle of the EF-2 loop (non-functional Ca<sup>2+</sup>-binding loop) (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Though the site appears to be surface exposed in the model, one should note that CHP3 has a 9-amino acid long insertion in that position as compared to CHP1 and CHP2 (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). The structure of CHP3 may deviate from the model and information for other conformations is lacking. Clearly, limited proteolysis showed that both sites are accessible and sufficiently flexible for productive cleavage in the free CHP3, yet become protected against cleavage upon complex formation. Both major cleavage sites are highly unlikely to be covered by CBD in the complex, as they are facing away from the target-binding pocket (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Thus, the drastic changes in the proteolytic stability indicate reduced flexibility in EF-2 and EF-4, which could be caused by structural rearrangements of CHP3 upon target peptide binding.</p></sec><sec id="s2-5"><title>Ca<sup>2+</sup> binding and the N-terminal myristoylation independently modulate the affinity of CHP3 for NHE1</title><p>To analyse how the conformational changes described above affect CHP3 function, we measured affinities of CHP3 and mCHP3 for the target peptide CBD with microscale thermophoresis (MST) in Ca<sup>2+</sup>- and in Mg<sup>2+</sup>-bound states. We used the system established earlier for quantification of binding affinities of CHP isoforms (CHP1, CHP2, and CHP3) to NHE1, in which the target peptide CBD was fused to maltose-binding protein (MBP-CBD) for its stabilization (<xref ref-type="bibr" rid="bib42">Liang et al., 2020</xref>; <xref ref-type="bibr" rid="bib17">Fuchs et al., 2018</xref>). We conducted the MST experiments with three biological replicates per sample and five individual titration series (technical replicates) per biological replicate (<xref ref-type="fig" rid="fig5">Figure 5</xref>). The dissociation constant (<italic>K</italic><sub>D</sub>) for a given sample was calculated with a global parameter estimation procedure including all biological and technical replicates. We fitted the mass action law to the MST data points using non-linear regression. Confidence intervals were assessed for each <italic>K</italic><sub>D</sub> value by calculating profile likelihoods (error surface plots) as described elsewhere (<xref ref-type="bibr" rid="bib36">Kreutz et al., 2013</xref>; <xref ref-type="bibr" rid="bib58">Scheuermann et al., 2016</xref>; <xref ref-type="fig" rid="fig5">Figure 5E</xref>). Comparison of the resulting <italic>K</italic><sub>D</sub> values showed that the effects of Ca<sup>2+</sup> binding and myristoylation on CHP3:CBD interaction are independent. Namely, Ca<sup>2+</sup> binding increased affinities for CBD of both non-myristoylated (CHP3:CBD, <italic>K</italic><sub>D</sub> = 3.1 [2.8; 3.4] nM) and myristoylated CHP3 (mCHP3:CBD, <italic>K</italic><sub>D</sub> = 5.6 [5.1; 6.2] nM) by about fivefold as compared to the Mg<sup>2+</sup>-bound state (CHP3:CBD, <italic>K</italic><sub>D</sub> = 14.6 [12.5; 16.9] nM; mCHP3:CBD, <italic>K</italic><sub>D</sub> = 28.2 [26.6; 29.8] nM) (<xref ref-type="fig" rid="fig5">Figure 5A–D</xref>). In turn, for both Ca<sup>2+</sup>- and Mg<sup>2+</sup>-bound states, myristoylation decreased the affinity twofold (<xref ref-type="fig" rid="fig5">Figure 5</xref>). Hence, CHP3 binds to NHE1 with nanomolar affinity in both open and closed conformation and independently of its modification, however, Ca<sup>2+</sup> binding and myristoylation modulates the affinity.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Ca<sup>2+</sup> binding and myristoylation independently affect the interaction between CHP3 and MBP-CBD as measured with microscale thermophoresis (MST).</title><p>The interaction of CHP3 (<bold>A, B</bold>) and mCHP3 (<bold>C, D</bold>) with MBP-CBD was measured with three biological replicates shown in different colours (each with five technical replicates) in the presence of either Ca<sup>2+</sup> (<bold>A, C</bold>) or Mg<sup>2+</sup> (<bold>B, D</bold>). The combined data from individual experiments were fitted with a one-site binding model using global non-linear regression. (<bold>E</bold>) 95% confidence intervals (Δ<italic>χ</italic><sup>2</sup> of 3.84) of <italic>K</italic><sub>D</sub>’s for CHP3:CBD and mCHP3:CBD calculated with profile likelihood method. Raw MST traces are shown in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83868-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Normalized microscale thermophoresis (MST) fluorescence timetraces of CHP3 and mCHP3 with MBP-CBD in the presence of either Mg<sup>2+</sup> or Ca<sup>2+</sup>.</title><p>Each graph contains measurements of one biological replicate (indicated with label (1), (2), (3)) with five technical replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83868-fig5-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-6"><title>Target peptide and Ca<sup>2+</sup> binding regulate the interaction of CHP3 with lipid membranes</title><p>As we showed that the effects of Ca<sup>2+</sup> and myristoylation on conformational changes of CHP3 and mCHP3 are independent, the hypothesis of a Ca<sup>2+</sup>-myristoyl switch for CHP3 (<xref ref-type="bibr" rid="bib24">Gutierrez-Ford et al., 2003</xref>; <xref ref-type="bibr" rid="bib72">Zaun et al., 2012</xref>) had to be questioned. Therefore, we analysed binding of CHP3 and mCHP3 to POPC:POPS (3:1 molar ratio) liposomes with a co-sedimentation assay in the presence of either Mg<sup>2+</sup> or Ca<sup>2+</sup>, and compared to the binding of recoverin, used as control protein for a Ca<sup>2+</sup>-myristoyl switch. In line with previous studies (<xref ref-type="bibr" rid="bib73">Zozulya and Stryer, 1992</xref>), non-myristoylated recoverin (Rec) only weakly interacted with liposomes in both Mg<sup>2+</sup>- and Ca<sup>2+</sup>-bound states, whereas the interaction of myristoylated protein (mRec) increased about fourfold upon Ca<sup>2+</sup> addition (<xref ref-type="fig" rid="fig6">Figure 6A, B</xref>). In the Mg<sup>2+</sup>-bound state, CHP3 interacted weakly with liposomes similar to recoverin, only a small protein amount co-sedimented with liposomes. In contrast to recoverin, Ca<sup>2+</sup> addition increased the binding of non-myristoylated CHP3 (about 2.5 times) to liposomes, whereas myristoylation did not further increase this binding (<xref ref-type="fig" rid="fig6">Figure 6A, B</xref>). Interestingly, the binding of the target peptide CBD substantially changed the interaction of CHP3 with liposomes. In both the absence and the presence of Ca<sup>2+</sup>, only a small amount of the CHP3:CBD complex was associated with liposomes. However, CHP3 myristoylation increased the binding in both conditions about fourfold (<xref ref-type="fig" rid="fig6">Figure 6A, B</xref>). In the presence of Ca<sup>2+</sup>, the binding of mCHP3:CBD was even slightly higher than without it, however the difference was not significant. These results indicate the following mode of interaction. The myristic moiety is located in the protein core of target-free CHP3 and is not accessible to lipid membranes in the presence of Ca<sup>2+</sup>. Most likely, other protein regions are involved in membrane binding in this case. Target peptide binding causes conformational rearrangements with displacement of the myristic moiety from the protein core to the environment, which leads in consequence to an increased association of CHP3 and its target to lipid membranes.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>The interaction of CHP3 and mCHP3 with liposomes is regulated by Ca<sup>2+</sup> and target peptide binding.</title><p>Proteins were co-sedimented with POPC:POPS (3:1 molar ratio) liposomes in the presence of either 2 mM Mg<sup>2+</sup> or 2 mM Mg<sup>2+</sup> + 2 mM Ca<sup>2+</sup> at 24°C. Non-myristoylated and myristoylated recoverin (Rec and mRec, respectively) were used as Ca<sup>2+</sup>-myristoyl switch control proteins. (<bold>A</bold>) Amount of proteins co-sedimented with liposomes was analysed with SDS–PAGE (4–12%, Bis-Tris). (<bold>B</bold>) Quantification of protein-liposome binding based on the densitometry of bands (SDS–PAGE shown in (<bold>A</bold>)) corresponded to the co-sedimented proteins with three biological (CHP3 and complexes) or technical (recoverin) replicates. Values were normalized to the respective non-myristoylated protein in the Mg<sup>2+</sup>-bound state. Data are shown as mean ± standard deviation (SD), one-way analysis of variance (ANOVA) with Tukey post-test was performed for mean comparison (statistical significance: n.s. – p &gt; 0.05, **p &lt; 0.01, ***p &lt; 0.001). (<bold>C</bold>) N-terminal myristoylation of target-associated CHP3 in mouse brain. LC–MS/MS analysis of a trypsin-digested size fraction of solubilized mouse brain membrane containing NHE1-associated CHP3 (see Materials and methods). Upper panel: high coverage of the mouse CHP3 primary sequence by MS/MS-identified peptides (in red; black: sequences not identified, grey: sequences not accessible to our MS analysis) without inclusion of N-myristoyl modification. Lower panel: MS/MS spectrum from the same measurement assigned to the myristoylated tryptic N-terminal peptide of CHP3. Note that no other forms of the N-terminal peptide were detectable in error-tolerant search. <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>: Full gels for (A) and replicates; raw data of band densitometry and ANOVA test p-values.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Full gels for <xref ref-type="fig" rid="fig6">Figure 6A</xref> and replicates; raw data of band densitometry and analysis of variance (ANOVA) test p-values for <xref ref-type="fig" rid="fig6">Figure 6B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83868-fig6-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83868-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Sequence coverage and N-terminal myristoylation of endogenous CHP3.</title><p>LC–MS/MS analysis of trypsin-digested total membrane fraction obtained from mouse platelets. Upper panel: coverage of the mouse CHP3 primary sequence by MS-identified peptides (in red; black: sequences not identified, grey: sequences not accessible to our MS analysis) without inclusion of N-myristoyl modification. Lower panel: MS/MS spectrum from the same measurement assigned to the myristoylated tryptic N-terminal peptide of CHP3. No other modifications of the N-terminus were detectable in error-tolerant search.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83868-fig6-figsupp1-v2.tif"/></fig></fig-group><p>Finally, we investigated the N-terminal myristoylation status of membrane associated CHP3 in vivo using liquid chromatography coupled mass spectrometry (LC–MS/MS). In three different preparations, namely (1) size fractionated complexes from mouse brain membranes (<xref ref-type="fig" rid="fig6">Figure 6C</xref>), (2) integral membrane proteins isolated from mouse platelets (i.e. after carbonate extraction, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>), and (3) anti-NHE1-affinity purification from solubilized mouse brain membranes (data not shown) we identified the vast majority of MS-accessible CHP3 peptides, but only the myristoylated form of the N-terminal peptide. Together, this suggests that myristoylated CHP3 is both NHE1 associated and membrane anchored in agreement with a target-induced exposure and membrane integration of the N-terminal myristoyl moiety.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Ca<sup>2+</sup>-induced conformational changes are a hallmark of Ca<sup>2+</sup>-sensing EFCaBPs, which control the interaction with and the function of specific target proteins (<xref ref-type="bibr" rid="bib7">Burgoyne, 2007</xref>). Our in vitro experiments show that Ca<sup>2+</sup> binding induces conformational changes in CHP3, thus it fulfills this prerequisite to respond to Ca<sup>2+</sup> signals in the cell. Based on the reported affinities of CHP3 for Ca<sup>2+</sup> and Mg<sup>2+</sup> (<xref ref-type="bibr" rid="bib24">Gutierrez-Ford et al., 2003</xref>), CHP3 should bind Mg<sup>2+</sup> at resting Ca<sup>2+</sup> concentration of about 0.1 µM in the cell (<xref ref-type="bibr" rid="bib57">Roderick and Cook, 2008</xref>; <xref ref-type="bibr" rid="bib4">Bootman and Bultynck, 2020</xref>) and it could bind Ca<sup>2+</sup> when intracellular Ca<sup>2+</sup> concentration rises up to 1 µM during signalling events (<xref ref-type="bibr" rid="bib4">Bootman and Bultynck, 2020</xref>). As CHP3 can be N-terminally myristoylated, it was proposed to be regulated with a so-called Ca<sup>2+</sup>-myristoyl switch mechanism (<xref ref-type="bibr" rid="bib24">Gutierrez-Ford et al., 2003</xref>; <xref ref-type="bibr" rid="bib72">Zaun et al., 2012</xref>), in which Ca<sup>2+</sup> binding induces the exposure of the myristic moiety to the environment. In contrast to this hypothesis, we described in the present study independent effects of Ca<sup>2+</sup> binding and N-terminal myristoylation on CHP3 conformation and on the interaction with its target protein NHE1. We show that target peptide and not Ca<sup>2+</sup> binding causes strong association of the myristoylated CHP3 to lipid membranes.</p><p>First, we optimized the protein production and purification to obtain pure myristoylated and non-myristoylated CHP3 devoid of affinity tags, a prerequisite for further quantitative biochemical and biophysical analysis. With the expression system based on that described for the production of N-myristoylated Nef protein of HIV-1 (<xref ref-type="bibr" rid="bib21">Glück et al., 2010</xref>), we obtained preparative amounts of fully myristoylated CHP3. Stoichiometric myristoylation, which is still challenging for recombinant EFCaBPs (<xref ref-type="bibr" rid="bib68">Vladimirov et al., 2020</xref>), was shown with native MS. The latter was also used to demonstrate that both CHP3 and mCHP3 bind a single Ca<sup>2+</sup>, and are thus functional EFCaBPs, in agreement with the results of equilibrium dialysis shown earlier (<xref ref-type="bibr" rid="bib24">Gutierrez-Ford et al., 2003</xref>). Using the highly pure proteins, we showed with FPH and intrinsic fluorescence assays reversible conformational changes in CHP3 between a more hydrophobic Ca<sup>2+</sup>-bound state typical for an open conformation and a less hydrophobic Mg<sup>2+</sup>-bound state reflecting a closed conformation (<xref ref-type="fig" rid="fig7">Figure 7</xref>). Such conformational changes are typical for Ca<sup>2+</sup> sensor EFCaBPs including calmodulin, recoverin, neuronal calcium sensor protein (NCS1), and others, and serve as a conformational switch for binding and/or regulation of a target protein (<xref ref-type="bibr" rid="bib9">Chazin, 2011</xref>). We characterized different CHP3 conformations in respect to thermal and proteolytic stability. We revealed a stabilizing effect of Mg<sup>2+</sup> on target-free CHP3 and mCHP3 with increased thermal stability. As we observed that CHP3 is not stable in the apo-state, we conclude that Mg<sup>2+</sup> binding is important to stabilize the closed conformation of target-free protein in the cell at resting Ca<sup>2+</sup> level. Stabilization by Mg<sup>2+</sup> binding has been shown for other EFCaBPs including calmodulin and troponin C (<xref ref-type="bibr" rid="bib20">Gifford and Vogel, 2013</xref>; <xref ref-type="bibr" rid="bib23">Grabarek, 2011</xref>). Further, replacement of Mg<sup>2+</sup> with Ca<sup>2+</sup> at EF-3 (C-lobe) lowered the thermal stability of CHP3 and mCHP3 and enhanced proteolytic cleavage in EF-2 (N-lobe) suggesting an increase in local flexibility. Thus, Ca<sup>2+</sup>-induced conformational changes involve not only the C-lobe of CHP3 but also its N-lobe.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Conformation of CHP3 is controlled by Ca<sup>2+</sup> and target peptide (NHE1 CBD) binding.</title><p>Ca<sup>2+</sup> (magenta) replaces Mg<sup>2+</sup> (green) in EF-3 and induces the transition from the closed to the open conformation. Ca<sup>2+</sup> binding affects the local flexibility in the N-lobe accelerating the tryptic cleavage and reduces the thermal stability of CHP3. In both, Ca<sup>2+</sup>- and Mg<sup>2+</sup>-bound states, CHP3 binds the target peptide CBD with nanomolar affinity (<italic>K</italic><sub>D</sub> values indicated, in brackets for myristoylated CHP3). Complex formation has no effect on the thermal stability of the Mg<sup>2+</sup>-bound state (closed conformation), whereas it strongly enhances thermal stability of the Ca<sup>2+</sup>-bound state (open conformation). Independent of the bound ion, both trypsin cleavage sites are protected from proteolysis in the CHP3:CBD complex.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83868-fig7-v2.tif"/></fig><p>The Ca<sup>2+</sup>-induced open conformation with lower thermal stability and increased local flexibility appears to provide the molecular basis for CHP3 to interact more readily with its target(s) (<xref ref-type="fig" rid="fig7">Figure 7</xref>). Our data support this hypothesis. Firstly, the binding of the target peptide resulted in a drastic increase of CHP3 thermal and proteolytic stabilities. However, the thermal stability increased only in the presence of Ca<sup>2+</sup>, whereas for the Mg<sup>2+</sup>-bound state it remained unchanged. These characteristics of the Ca<sup>2+</sup>-induced open conformation may lower the energy barrier for binding of the target peptide. Secondly, in line with co-immunoprecipitation of tagged NHE1 and tagged CHP3 from transfected AP-1 cells (<xref ref-type="bibr" rid="bib72">Zaun et al., 2012</xref>), we detected binding between CHP3 and CBD in both, Ca<sup>2+</sup>- and Mg<sup>2+</sup>-bound states (see <xref ref-type="fig" rid="fig5">Figure 5</xref>). The quantitative analysis with MST showed that the affinity of the Ca<sup>2+</sup>-bound state was about five times higher, clearly indicating that Ca<sup>2+</sup> controls CHP3 function.</p><p>Though all CHP isoforms bind NHE1 with nanomolar affinities in the absence and presence of Ca<sup>2+</sup> (<xref ref-type="bibr" rid="bib42">Liang et al., 2020</xref>; <xref ref-type="bibr" rid="bib17">Fuchs et al., 2018</xref>), intracellular Ca<sup>2+</sup> signals might regulate NHE1 function (e.g. activity or stability) via CHPs affecting the conformation of the complex. Regulation of the activity by Ca<sup>2+</sup> binding to the regulatory subunit was described for calcineurin, a phosphatase consisting of the catalytic and regulatory subunits calcineurin A (CnA) and B (CnB), respectively. Similar to the CHP3:NHE1 interaction, CnB forms a stable complex with CnA independently of Ca<sup>2+</sup> binding. Nevertheless, Ca<sup>2+</sup> binding induces conformational changes of CnB resulting in the release of the calmodulin-binding domain of CnA and allowing its activation by calmodulin (<xref ref-type="bibr" rid="bib10">Creamer, 2020</xref>; <xref ref-type="bibr" rid="bib70">Yang and Klee, 2000</xref>). In the case of CHPs, and particularly of CHP3, Ca<sup>2+</sup> binding to the C-terminal EF-hands (EF-3 in CHP3) affects the conformation also of the N-terminal lobe (<xref ref-type="fig" rid="fig7">Figure 7</xref>), most likely via the hydrophobic cluster at the interface between N- and C-lobes, which is characteristic for the so-called CPV (calcineurin B, p22/CHP1, visinin) subfamily of EFCaBPs (<xref ref-type="bibr" rid="bib30">Kawasaki and Kretsinger, 2017</xref>). Such conformational changes of CHP might affect the overall structure of the complex formed by CHPs and NHE1. All CHP structures so far, the recent cryo-EM structure of the NHE1:CHP1 complex (<xref ref-type="bibr" rid="bib13">Dong et al., 2021</xref>), and structures of CHP1 (<xref ref-type="bibr" rid="bib47">Mishima et al., 2007</xref>) and CHP2 (<xref ref-type="bibr" rid="bib2">Ammar et al., 2006</xref>) in complex with the target peptide CBD obtained with NMR and X-ray crystallography, showed one conformation of CHPs with Ca<sup>2+</sup> (or the Ca<sup>2+</sup>-mimic Y<sup>3+</sup>) and the target peptide bound. The structure of CHP3 has not been determined so far and moreover, structural information of target-free CHPs in the open and closed conformations is lacking. Therefore, further structural studies are required to better understand the molecular mechanisms for NHE1 regulation by Ca<sup>2+</sup> binding to CHPs. This information would be valuable also to elucidate signal integration through the regulatory domain of NHE1, which acts as signalling hub interacting with several regulatory proteins including the Ca<sup>2+</sup>-binding proteins calmodulin and calcineurin (<xref ref-type="bibr" rid="bib54">Pedersen and Counillon, 2019</xref>).</p><p>Regarding the lipidation modification, many Ca<sup>2+</sup> sensor proteins have an N-terminal myristoylation site and often Ca<sup>2+</sup> binding to the myristoylated EFCaBP causes an exposure of the myristoyl moiety. A surface-exposed myristoyl moiety strongly increases the binding of the Ca<sup>2+</sup>-bound EFCaBP to lipid membranes. This regulatory mechanism is called Ca<sup>2+</sup>-myristoyl switch and was described for a subgroup of neuronal calcium sensor (NCS) proteins (recoverin, hippocalcin, visinin-like proteins, and neurocalcin δ) (<xref ref-type="bibr" rid="bib1">Ames et al., 1997</xref>; <xref ref-type="bibr" rid="bib6">Burgoyne, 2004</xref>). In other NCSs, the position of the myristoyl moiety is not affected by calcium binding, but it is constantly exposed (NCS1, KChIP1) (<xref ref-type="bibr" rid="bib46">McFerran et al., 1999</xref>; <xref ref-type="bibr" rid="bib51">O’Callaghan et al., 2003</xref>) or hidden inside the protein (GCAP1, GCAP2) (<xref ref-type="bibr" rid="bib43">Lim et al., 2014</xref>; <xref ref-type="bibr" rid="bib7">Burgoyne, 2007</xref>; <xref ref-type="bibr" rid="bib6">Burgoyne, 2004</xref>). So far, there is no apparent correlation between number and position of active EF-hands with the position of the myristoyl moiety in NCS proteins. Even for highly homologous myristoylated NCS proteins with known structures, the location of the myristoyl moiety varies (<xref ref-type="bibr" rid="bib43">Lim et al., 2014</xref>). Thus, structural information and models are not sufficient to assign a calcium-myristoyl switch. For CHP3, a Ca<sup>2+</sup>-myristoyl switch was proposed as mutational analysis indicated that deficiency in Ca<sup>2+</sup> binding and/or myristoylation of CHP3 reduced the surface expression and activity of NHE1 in the same degree (<xref ref-type="bibr" rid="bib72">Zaun et al., 2012</xref>). Yet, a direct evidence for a Ca<sup>2+</sup>-myristoyl switch in CHP3 was lacking. Our data indicate an independent regulation of CHP3 by Ca<sup>2+</sup> binding and myristoylation, and contradict the presence of a Ca<sup>2+</sup>-myristoyl switch. Firstly, CHP3 myristoylation only slightly increased the hydrophobicity of the Ca<sup>2+</sup>-bound state in comparison to the prominent hydrophobicity increase of recoverin that has a classical Ca<sup>2+</sup>-myristoyl switch (<xref ref-type="bibr" rid="bib1">Ames et al., 1997</xref>). Secondly, myristoylation did not affect Ca<sup>2+</sup>-binding properties of CHP3. Next, myristoylation reduced the thermal stability of free and target-bound CHP3 in a similar manner for both Ca<sup>2+</sup>- and Mg<sup>2+</sup>-bound states. Furthermore, mCHP3 affinities to CBD in both ion-bound states were decreased twofold compared to CHP3. We also provided further evidence for the lack of a Ca<sup>2+</sup>-myristoyl switch in CHP3 by analysing its interaction with liposomes. Although Ca<sup>2+</sup> addition strongly increased the CHP3 association with POPC/POPS liposomes, the effect was the same for both myristoylated and non-myristoylated proteins. In the closed conformation, the myristic group is usually buried in the protein core of EFCaBPs, however the binding interface differs a lot in different EFCaBPs (<xref ref-type="bibr" rid="bib43">Lim et al., 2014</xref>). We assume that CHP3 resembles GCAPs, which have the myristoyl group enclosed in the protein hydrophobic core independently of Ca<sup>2+</sup> binding (<xref ref-type="bibr" rid="bib43">Lim et al., 2014</xref>). The membrane binding of CHP3 independent of its myristoylation suggests that different protein regions, for example clusters of hydrophobic or positively charged residues, are involved in proteinlipid interaction. Binding of the target peptide CBD drastically reduced the interaction of CHP3 with lipid membranes that is apparently caused by large structural rearrangements. The CHP3:CBD complex did not bind to liposomes in the presence of Ca<sup>2+</sup>. One can speculate that residues involved in membrane binding of the target-free Ca<sup>2+</sup>-bound CHP3 can be either covered by the target peptide or become inaccessible due to structural rearrangements upon complex formation. In stark contrast to the target-free CHP3, myristoylation increased fourfold the amount of CHP3:CBD complex associated with liposomes. We propose that the target peptide competes with the myristoyl moiety for binding in the hydrophobic pocket and by this way shifts the conformational equilibrium of CHP3, resulting in the exposure of the myristoyl moiety to the environment (<xref ref-type="fig" rid="fig8">Figure 8</xref>). The competition for the hydrophobic pocket is also in line with the lower affinity of mCHP3 to CBD in comparison to non-myristoylated protein as shown by MST analysis (<xref ref-type="fig" rid="fig5">Figure 5</xref>). As the effect on affinity is small, the myristoyl moiety binds most likely weakly or transiently to the target-binding pocket. This resembles the dynamic regulatory interaction of disordered protein regions of p53 to its DNA-binding domain (<xref ref-type="bibr" rid="bib38">Krois et al., 2018</xref>) and of Radical-Induced Cell Death 1 (RCD1) to the ligand-binding pocket (<xref ref-type="bibr" rid="bib60">Staby et al., 2021</xref>).</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Target-myristoyl switch in CHP3.</title><p>N-terminal myristoylation of CHP3 by NMT1 increases the local flexibility in the N-lobe, as it accelerated its tryptic cleavage. The myristoyl moiety most likely binds weakly or transiently to the target-binding pocket in both Ca<sup>2+</sup>- and Mg<sup>2+</sup>-bound states, as myristoylation reduced twofold the affinity of CHP3 to CBD. CBD binding causes displacement from the hydrophobic pocket and the surface exposure of the myristoyl moiety resulting in enhanced CHP3 binding to lipid membranes in both Ca<sup>2+</sup>- and Mg<sup>2+</sup>-bound states.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83868-fig8-v2.tif"/></fig><p>In general, the surface exposure of the myristoyl moiety in myristoylated regulatory proteins can be induced by Ca<sup>2+</sup> or by small molecule binding, phosphorylation, and pH shift. Respective regulatory mechanisms were termed Ca<sup>2+</sup>-myristoyl switch (neuronal calcium sensor proteins) (<xref ref-type="bibr" rid="bib1">Ames et al., 1997</xref>; <xref ref-type="bibr" rid="bib6">Burgoyne, 2004</xref>), GTP-myristoyl switch (ARF1 GTPase [<xref ref-type="bibr" rid="bib22">Goldberg, 1998</xref>]), myristoyl/phosphoserine switch (<xref ref-type="bibr" rid="bib5">Braun et al., 2000</xref>; <xref ref-type="bibr" rid="bib18">Gaffarogullari et al., 2011</xref>), and pH-dependent myristoyl switch (hisactophilin [<xref ref-type="bibr" rid="bib26">Hanakam et al., 1996</xref>]). The myristoyl switch induced by proteinprotein interaction described here for CHP3 is a novel mechanism that regulates the association of myristoylated proteins with lipid membranes. We propose to call it ‘target-myristoyl switch’ (<xref ref-type="fig" rid="fig8">Figure 8</xref>). This mechanism was supported by LC–MS/MS analyses, which exclusively detected the N-terminally myristoylated CHP3 in brain membrane fraction (<xref ref-type="fig" rid="fig6">Figure 6C</xref>) and in a preparation from platelets containing integral membrane proteins and lipid-anchored proteins (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). We suggest that the target-myristoyl switch is the canonical mechanism to anchor the regulatory domain of NHE1 to the plasma membrane, which appears to be the molecular basis for an increase of NHE1 surface stability by CHP3. A defined conformation enforced by the membrane anchor may also regulate NHE1 activity. As the second mode of regulation, Ca<sup>2+</sup> binding to CHP3 can affect NHE1:CHP3 interaction in two ways. Ca<sup>2+</sup> directly increases the binding affinity of CHP3 for NHE1, and indirectly increases the probability to interact with NHE1 via enhanced association of free CHP3 with lipid membranes. Our hypothesis is in line with the previous observation that both, CHP3 myristoylation and Ca<sup>2+</sup> binding are important for NHE1 surface stability when both proteins were co-expressed in AP-1 cell line (<xref ref-type="bibr" rid="bib72">Zaun et al., 2012</xref>).</p><p>It will be interesting to investigate whether the interaction of CHP3 with other described target proteins, such as with subunit 4 of COP9 signalosome, GSK3ß, and calcineurin A (<xref ref-type="bibr" rid="bib24">Gutierrez-Ford et al., 2003</xref>; <xref ref-type="bibr" rid="bib40">Levay and Slepak, 2014</xref>; <xref ref-type="bibr" rid="bib33">Kobayashi et al., 2015</xref>) can induce the target-myristoyl switch and how Ca<sup>2+</sup> binding affects these interactions. Structural characterization of CHP3 in different conformations is needed to further explore the underlying molecular basis of the regulatory mechanism. The target-myristoyl switch might exist in other proteins including CHP1 and CHP2 and can be explored by comparison of the membrane association for myristoylated and non-myristoylated complexes.</p><p>CHP3 is an emerging important player in the cellular Ca<sup>2+</sup> signalling network that is involved in regulation of cancerogenesis, cardiac hypertrophy, and neuronal development. Our data can help to better understand the molecular mechanisms of regulation of these processes by CHP3 and of signal integration by NHE1.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pETDuet-1Δ6His_hNMT_Nef</td><td align="left" valign="bottom">DOI:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0010081">10.1371/journal.pone.0010081</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Provided by Prof. Willbold (Forschungszentrum Jülich, Germany)</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Bovine serum albumin (BSA)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat.# A7906</td><td align="left" valign="bottom">For production of mCHP3 and mRec</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Trypsin</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat.# T1426</td><td align="left" valign="bottom">For limited trypsinolysis</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Myristic acid</td><td align="left" valign="bottom">Carl Roth GmbH</td><td align="left" valign="bottom">Cat.# 6469.1</td><td align="left" valign="bottom">For production of mCHP3 and mRec</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">POPC</td><td align="left" valign="bottom">Avanti Polar Lipids, Inc</td><td align="left" valign="bottom">Cat.# 850457C</td><td align="left" valign="bottom">Liposome preparation</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">POPS</td><td align="left" valign="bottom">Avanti Polar Lipids, Inc</td><td align="left" valign="bottom">Cat.# 840034C</td><td align="left" valign="bottom">Liposome preparation</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">ProteOrange</td><td align="left" valign="bottom">Lumiprobe</td><td align="left" valign="bottom">Cat.# 40210</td><td align="left" valign="bottom">Dye for FPH assay</td></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">Monolith Series Protein labeling kit – RED-NHS</td><td align="left" valign="bottom">Nanotemper Technologies</td><td align="left" valign="bottom">Cat.# MO-001</td><td align="left" valign="bottom">MST labeling kit</td></tr><tr><td align="left" valign="bottom">Commercial assay, kit</td><td align="left" valign="bottom">Monolith Series Premium Capillaries</td><td align="left" valign="bottom">Nanotemper Technologies</td><td align="left" valign="bottom">Cat.# MO-K025</td><td align="left" valign="bottom">MST capillaries</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Data2Dynamics Software</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/Data2Dynamics/d2d">https://github.com/Data2Dynamics/d2d</ext-link>; <xref ref-type="bibr" rid="bib37">Kreutz, 2023</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">For statistical analysis of datasets consisted of technical and biological replicates</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">16% Novex Tricine Gel</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat.# EC66955BOX</td><td align="left" valign="bottom">SDS–PAGE system for separation of CHP3 and mCHP3</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">96-well black plates</td><td align="left" valign="bottom">Greiner Bio-One</td><td align="left" valign="bottom">Cat.# 655076</td><td align="left" valign="bottom">For FPH assay</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Plasmids</title><p>The generation of all plasmids was performed using NEBuilder HiFi DNA assembly Master Mix (New England Biolabs GmbH, Frankfurt, Germany). Protein-coding sequences (CDS) were inserted without any additions for affinity tags if not stated otherwise. The pETDuet-1Δ6His_hNMT_Nef containing the codon optimized CDS of the human N-myristoyltransferase 1 (NMT1, Gene ID 4836, UniProtKB ID P30419) was kindly provided by Prof. Willbold (Forschungszentrum Jülich, Germany). To obtain the pETDuet1_NMT1_TESC plasmid, the codon optimized (<italic>E. coli</italic>) CDS of human CHP3 (TESC, Gene ID 54997, UniProtKB ID Q96BS2) was cloned into the second multiple cloning site of the pETDuet-1Δ6His_hNMT_Nef plasmid replacing the Nef CDS. The NMT1 CDS was deleted from the pETDuet1_NMT1_TESC plasmid to generate the plasmid pETDuet1_TESC. For co-expression of the NHE1 CBD:CHP3 complexes, the codon optimized (<italic>E. coli</italic>) CDS of a minimal NHE1 CBD with three additional histidines added C-terminally (NHE1 residues 525–545, MRSINEEIHTQFLDHLLTGIEDICGHYGHHHHHH, CBDHis) was used. In case of the pETDuet1_CBDHis_TESC plasmid, the CBDHis CDS was inserted in the first multiple cloning site, whereas for the pETDuet1_NMT1_CBDHis_TESC plasmid, the CBDHis CDS, and the linker region containing T7 promoter/lac operator and ribosome-binding site was inserted between NMT1 and CHP3 CDSs. The plasmid pETDuet1_Rec containing the codon optimized CDS of human recoverin (Gene ID 5957, UniProtKB ID P35243) in the second multiple cloning site was obtained from BioCat (Heidelberg, Germany). NMT1 CDS was inserted into the first site of this plasmid to obtain the pETDuet1_NMT1_Rec plasmid.</p></sec><sec id="s4-2"><title>Protein productions and purifications</title><p>We adapted the protocol of <xref ref-type="bibr" rid="bib21">Glück et al., 2010</xref> for the production of recombinant myristoylated CHP3 (mCHP3) by co-expression with human NMT1. Pre-cultures in TB<sup>carb</sup> medium were made from a single colony of <italic>E. coli</italic> BL21 (DE3) transformed with the pETDuet1_NMT1_TESC plasmid. Main cultures in TB<sup>carb</sup> medium containing the surfactant Antifoam 204 (Merck KGaA, Darmstadt, Germany) were inoculated to a final OD<sub>600</sub> = 0.1 and incubated at 37°C. At OD<sub>600</sub> = 0.6, the temperature was shifted to 28°C and 3% ethanol (vol/vol) was added. Myristic acid (mixed with 4% bovine serum albumin) was added at OD<sub>600</sub> = 0.70–0.75. The protein production was induced at OD<sub>600</sub> = 0.8 with 0.5 mM IPTG (isopropyl β-D-1-thiogalactopyranoside). After 4-hr incubation, cells were harvested and stored at −80°C. Non-myristoylated CHP3 was produced similarly using the plasmid without NMT1 (pETDuet1_TESC); no antifoam, ethanol and myristic acid were added to the medium. The expression was performed at 30°C overnight.</p><p>All chromatography columns were obtained from Cytiva (Marlborough, MS, USA). CHP3 and mCHP3 were purified using Ca<sup>2+</sup>-dependent HIC based on protocols established for other EFCaBPs (<xref ref-type="bibr" rid="bib62">Tanaka et al., 1984</xref>; <xref ref-type="bibr" rid="bib69">Wei and Lee, 1997</xref>). Briefly, sedimented cells were resuspended in buffer A (20 mM HEPES (4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid), 150 mM NaCl, 10 mM DTT (dithiothreitol), 10% glycerol [wt/vol], pH 7.2) containing 10 mM CaCl<sub>2</sub> and 0.3 mM Pefabloc (Carl Roth GmbH, Karlsruhe, Germany), and lysed with a cell disruptor (Constant systems, Daventry, UK). Cell debris was removed by centrifugation and the supernatant was loaded onto a HiPrep 16/10 Phenyl HP column equilibrated with buffer A containing 10 mM CaCl<sub>2</sub>. After removal of unbound material with 10 column volumes of the equilibration buffer, the protein was eluted with buffer A containing 10 mM EGTA (ethylene glycol bis(2-aminoethyl ether)-N,N,N´,N´-tetraacetic acid), and the eluate was mixed with an equal volume of buffer A containing 10 mM MgCl<sub>2</sub>. The eluted protein was concentrated and loaded onto a pre-equilibrated HiLoad 26/600 Superdex 75 column. Buffer A containing 10 mM MgCl<sub>2</sub> was used as a running buffer. Fractions containing the purified protein were pooled, concentrated, mixed 1:1 with the cryo-storage buffer (2 M sucrose in gel filtration buffer), flash frozen in liquid nitrogen, and stored at −80°C.</p><p>Recoverin and mRecoverin were produced and purified as described above for CHP3 and mCHP3 using the pETDuet1_Rec and pETDuet1_NMT1_Rec plasmids, respectively. The fusion construct of maltose-binding protein and NHE1 CBD (MBP-CBD) was produced and purified as described previously (<xref ref-type="bibr" rid="bib17">Fuchs et al., 2018</xref>).</p><p>The production of CHP3:CBD and mCHP3:CBD complexes was performed as described above using pETDuet1_CBDHis_TESC or pETDuet1_NMT1_CBDHis_TESC plasmids, respectively. Cells were lysed in the presence of 20 mM imidazol. The complexes were purified by IMAC followed by gel filtration. Cell lysate was loaded onto a HisTrap FF 5 ml column pre-equilibrated with buffer A containing 10 mM CaCl<sub>2</sub> and 20 mM imidazol. After removal of unbound material with 10 column volumes of the equilibration buffer, elution was done with a linear gradient from 20 to 600 mM imidazol over 20 column volumes. For gel filtration, buffer A containing 10 mM CaCl<sub>2</sub> was used as a running buffer.</p></sec><sec id="s4-3"><title>Native mass spectrometry</title><p>The degree of myristoylation was determined by native MS. For native ion mobility separation (IM)-MS analysis, proteins were transferred into 200 mM ammonium acetate, pH 6.7. Capillaries for nanoflow ESI were prepared in-house from borosilicate glass capillaries 1.0 mm OD × 0.78 mm ID (Harvard Apparatus, Holliston, MA, USA) using a micropipette puller Model P-97 (Sutter Instruments, Novato, CA, USA) and coated with gold using a sputter coater 108 auto (Cressington TESCAN GmbH, Dortmund, Germany). 3–5 µl of 20 µM protein were loaded per experiment. Measurements were carried out with quadrupole-IM-MS-ToF instrument Synapt G1 HDMS (Waters Corporation, Milford, MA, USA and MS Vision, Almere, The Netherlands) equipped with a 32,000 <italic>m/z</italic> range quadrupole. Pressures were 8 mbar backing in the source, 0.017 mbar argon in the trap and transfer collision cell and 0.5 mbar nitrogen in the ion mobility cell. Instrument parameters were as follow: capillary voltage 1.2 kV, source temperature 60°C, sample cone voltage 100 V, extraction cone voltage 10 V, acceleration voltages in the trap and transfer cell 5 and 35 V, respectively, IM bias potential 22 V, wave velocity and height 300 m/s and 8 V. Spectra were acquired in the positive ion mode in the <italic>m/z</italic> range 1000–6000. Spectra recorded for cesium iodide at 50 mg/ml in 50% (vol/vol) isopropanol were used for external mass calibration. Data were processed and analysed using MassLynx Software version 4.1 (Waters Corporation) and UniDec version 2.7.3 (<xref ref-type="bibr" rid="bib45">Marty et al., 2015</xref>). For charge state deconvolution, smoothing and subtraction of linear background from raw spectra were done.</p></sec><sec id="s4-4"><title>MS sequencing of native CHP3</title><p>Mouse brain membranes were prepared, solubilized with ComplexioLyte 47 (Logopharm, Germany) and protein complexes were separated by BN-PAGE as described (<xref ref-type="bibr" rid="bib59">Schwenk et al., 2012</xref>). A section corresponding to an apparent molecular weight of 630 kDa (the migration size of native NHE1 complexes) was excised and subjected to MS analysis (as described below). Mouse platelets were prepared from fresh blood by differential centrifugation and 20 µg washed with 50 µl 100 mM Na<sub>2</sub>CO<sub>3</sub> pH 11 (10 min at 4°C, followed by ultracentrifugation at 233,000 × <italic>g</italic> for 20 min). The resulting pellet was dissolved in Laemmli buffer and separated on an SDS–PAGE gel and silver stained. The section &lt;50 kDa was excised, in-gel digested with trypsin, the peptides were dissolved in 20 µl 0.5% (vol/vol) trifluoroacetic acid, and 1 µl was analysed on an LC–MS/MS setup (UltiMate 3000 RSLCnano HPLC/QExactive HF-X mass spectrometer, both Thermo Scientific, Germany) as described (<xref ref-type="bibr" rid="bib34">Kollewe et al., 2021</xref>). MS/MS data were extracted and searched against the UniProtKB/Swiss-Prot database (mouse, rat, human, release 20220525; Mascot search engine version 2.7, Matrix Science, UK) with the following settings: Acetyl (Protein N-term), Carbamidomethyl (C), Gln-&gt;pyro-Glu (N-term Q), Glu-&gt;pyro-Glu (N-term E), Oxidation (M), Propionamide (C) as variable modifications, one missed cleavage allowed, with or without myristoylation (N-term G) or in error-tolerant mode; precursor/fragment mass tolerance was ±10 ppm/±25 mmu, significance threshold p &lt; 0.05.</p></sec><sec id="s4-5"><title>Fluorescence-based assays</title><p>The conformational changes of the protein in response to ion binding were probed with the FPH assay (<xref ref-type="bibr" rid="bib42">Liang et al., 2020</xref>) and by monitoring the intrinsic tryptophan fluorescence. The buffer of the protein solution was exchanged to the assay buffer (20 mM HEPES, 150 mM NaCl, 1 mM TCEP (Tris(2-carboxyethyl)phosphin), 2 mM MgCl<sub>2</sub>, pH 7.2) containing 1 mM EGTA using Zeba spin desalting columns (Thermo Fisher Scientific Inc, Waltham, MA, USA). The FPH assay was modified as follows. 500 µl of 1.5 µM protein and 5 µM ProteOrange (Lumiprobe GmbH, Hannover, Germany) in the assay buffer were mixed and incubated for 30 min in the dark. The fluorescence at 585 nm (excitation at 470 nm) was measured continuously with the Cary Eclipse spectrofluorimeter (Agilent Technologies, Santa Clara, CA, USA). Every 60 s a new compound was added in the following order: 2 mM CaCl<sub>2</sub>, 3 mM EGTA, 3 mM EDTA (ethylenediaminetetraacetic acid), and 4 mM CaCl<sub>2</sub>.</p><p>Determination of Ca<sup>2+</sup> EC50 values was performed using the FPH assay, mixing 1.5 µM protein and 5 µM ProteOrange with varied (0.34 µM to 8.0 mM) concentrations of CaCl<sub>2</sub>. The assay was carried out in 96-well black plates (Greiner Bio-One, Frickenhausen, Germany) with a sample volume of 100 μl. For each biological replicate, three to four technical replicates were measured. The fluorescence at 590 nm with excitation at 485 nm (<italic>F</italic><sub>590</sub>) was measured with the BioTek Synergy 2 plate reader (Agilent Technologies, Santa Clara, CA, USA). The data were fitted using the Hill equation<disp-formula id="equ1"><mml:math id="m1"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mn>590</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">C</mml:mi><mml:msup><mml:mi mathvariant="normal">a</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mo>+</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mn>50</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">C</mml:mi><mml:msup><mml:mi mathvariant="normal">a</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mo>+</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>to estimate parameters from data which has the a priori unknown parameters: <italic>F</italic><sub>0</sub> (<italic>F</italic><sub>590</sub> in the absence of Ca<sup>2+</sup>), <italic>F</italic><sub>max</sub> (maximal change of <italic>F</italic><sub>590</sub>), EC50, and <italic>n</italic> (Hill coefficient). The parameters EC50 and the Hill coefficient <italic>n</italic> represent biological quantities that are global and therefore shared between the three biological replicates. The parameters <italic>F</italic><sub>0</sub> and <italic>F</italic><sub>max</sub> are affected by experimental procedures and therefore different between the three biological replicates. Adding one parameter for dose-independent measurement noise, a total of nine parameters has to be estimated simultaneously for each condition. Parameter uncertainty can be assessed using the profile likelihood method, which is also referred to as error surface plots. We utilized optimization to obtain the best parameter set that minimizes deviation between model and data in terms of the negative log-likelihood. Uncertainty of the parameters is quantified using profile likelihood method (<xref ref-type="bibr" rid="bib36">Kreutz et al., 2013</xref>), which is also termed error surface plots in the literature. This fitting procedure was independently applied to both conditions in order to obtain EC50 values and corresponding uncertainties for both conditions. Data2Dynamics Software (<xref ref-type="bibr" rid="bib56">Raue et al., 2015</xref>) used for EC50 determination from data including biological and technical replicates is available at GitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/Data2Dynamics/d2d">https://github.com/Data2Dynamics/d2d</ext-link>, copy archived at <xref ref-type="bibr" rid="bib37">Kreutz, 2023</xref>).</p><p>For monitoring the intrinsic tryptophan fluorescence, 500 µl of 2.5 µM of the respective protein in assay buffer were prepared. Fluorescence was measured at 330 nm with an excitation at 280 nm. The time traces were recorded as described above for the FPH assay. For the tryptophan fluorescence spectra, a protein concentration of 5 µM was used and emission spectra of CHP3 and mCHP3 were measured from 300 to 380 nm (excitation at 280 nm) in the presence of 2 mM Mg<sup>2+</sup> plus 1 mM EGTA and with further addition of 2 mM Ca<sup>2+</sup>.</p><p>All assays were performed with three individually purified biological replicates of CHP3 and mCHP3.</p></sec><sec id="s4-6"><title>Thermal stability analysis with nanoDSF</title><p>The thermal stability of CHP3, mCHP3, and the complexes with CBD was compared at different conditions using nano differential scanning fluorimetry (nanoDSF). Buffer of the protein solutions was exchanged to the assay buffer as above; the final concentration was adjusted to 100 µM and thermal stability was measured in the presence of 10 mM of either MgCl<sub>2</sub>, CaCl<sub>2</sub>, MgCl<sub>2</sub> and CaCl<sub>2</sub>, or EDTA. Each sample was measured with two technical and three independent biological replicates in standard capillaries (Nanotemper Technologies, Munich, Germany) with the Prometheus NT.48 device (Nanotemper Technologies). Measurements were carried out from 20 to 95°C with a heating rate of 1°C/min. Unfolding of proteins analysed was irreversible, thus apparent melting temperatures (<italic>T</italic><sub>m</sub><sup>app</sup>) are given. They were determined as an inflection point of the unfolding curves using the PR.ThermControl software (Nanotemper Technologies).</p></sec><sec id="s4-7"><title>Limited proteolysis</title><p>Next, we probed the proteolytic stability of CHP3, mCHP3, and of their complexes with CBD. Buffer of the protein solutions was exchanged to the assay buffer containing either 2 mM MgCl<sub>2</sub> + 0.5 mM EGTA, 2 mM CaCl<sub>2</sub>, 2 mM MgCl<sub>2</sub> + 2 mM CaCl<sub>2</sub>, or 2 mM EDTA as an additive. The final protein concentration was adjusted to 0.5 mg/ml for each sample. Each reaction was started with the addition of 0.01 mg/ml trypsin (Sigma Aldrich, Cat. No. T1426) dissolved in 1 mM HCl, and performed for 1 hr on ice. Samples were taken after 5, 15, 30, 45, and 60 min, directly mixed with an equal volume of 2× reducing NuPAGE LDS sample buffer (Thermo Fisher Scientific) and boiled for 5 min at 95°C. The proteolytic fragments were separated on 12% NuPAGE Bis-Tris gels (Thermo Fisher Scientific).</p><p>To determine which trypsin cleavage sites in CHP3 are accessible for proteolysis, the major proteolytic fragments were analysed by ESI MS. 100 µl of CHP3 and mCHP3 in the assay buffer with 2 mM CaCl<sub>2</sub> and 2 mM MgCl<sub>2</sub> were incubated with trypsin for 15 min. Protein fragments were separated on 16% Novex Tricine gels (Thermo Fisher Scientific). The major bands were cut, minced into smaller pieces and loaded on top of 300 kDa Nanosep centrifugal devices (Pall Corporation, Port Washington, NY, USA). Proteins were eluted two times with 400 µl of the assay buffer containing 0.1% SDS by centrifugation at 14,000 × <italic>g</italic> for 20 min. Eluates were concentrated with Vivaspin500 5,000 MWCO concentrators (Sartorius AG, Goettingen, Germany). SDS was removed by precipitation with 0.2 M KCl followed by 10 min centrifugation at 14,000 × <italic>g</italic>. 10 µl of each sample were analysed with liquid chromatography (Thermo Fisher Ultimate 3000 with Phenomenex Jupiter 5 µm C4 300 Å 50 × 2 mm) coupled to high-resolution ESI MS (Maxis 4G, Bruker Corporation, Billerica, MA, USA). The resulting peptide masses were compared to all possible trypsin digestion fragments of CHP3 or mCHP3 to identify the cleavage sites.</p></sec><sec id="s4-8"><title>Microscale thermophoresis</title><p>MST was performed using the Monolith Pico device (Nanotemper Technologies) as described previously (<xref ref-type="bibr" rid="bib17">Fuchs et al., 2018</xref>). The only difference was the use of the measuring buffer containing either 10 mM CaCl<sub>2</sub> or 10 mM MgCl<sub>2</sub> (20 mM HEPES, 5 mM TCEP, 150 mM NaCl, 0.05% Tween-20, 10 mM MgCl<sub>2</sub>, or 10 mM CaCl<sub>2</sub>; pH 7.2). All measurements were performed with three independently produced and purified protein replicates of CHP3, mCHP3, and MBP-CBD. Every condition was titrated and measured five times per biological replicate (technical replicates).</p><p>Mass action kinetics of a one-site binding model was utilized to derive the fitting function for dissociation constant (<italic>K</italic><sub>D</sub>) determination: Let <italic>A</italic> and <italic>B</italic>* denote the concentrations of unlabelled and labelled binding partners respectively, and the concentration of the protein complex by <italic>AB</italic>*. The total amounts of <italic>A</italic> and <italic>B</italic>* (<inline-formula><mml:math id="inf1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>B</mml:mi><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula>) can be controlled by the experimental setup. In our application, <inline-formula><mml:math id="inf3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msubsup><mml:mi>B</mml:mi><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:mstyle></mml:math></inline-formula> =10 nM was fixed and <inline-formula><mml:math id="inf4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> =[MBP-CBD] was the independent variable for the dose response analysis. The thermophoresis data were normalized and fitted with global non-linear regression to the dose response function (<xref ref-type="bibr" rid="bib58">Scheuermann et al., 2016</xref>):<disp-formula id="equ2"><mml:math id="m2"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:msup><mml:mi>B</mml:mi><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup><mml:msubsup><mml:mi>B</mml:mi><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msubsup></mml:mfrac><mml:mo>⋅</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:msup><mml:mi>B</mml:mi><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mi>A</mml:mi><mml:msup><mml:mi>B</mml:mi><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:msubsup><mml:mi>B</mml:mi><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msubsup></mml:mfrac><mml:mo>⋅</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi>A</mml:mi><mml:msup><mml:mi>B</mml:mi><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>with <inline-formula><mml:math id="inf5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> – thermophoresis (change of normalized fluorescence) as a function of MBP-CBD concentration, <inline-formula><mml:math id="inf6"><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mi>*</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf7"><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi>A</mml:mi><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mi>*</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:math></inline-formula> – thermophoresis of the labelled partner and the complex, respectively. The concentration of the complex is given by<disp-formula id="equ3"><mml:math id="m3"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>A</mml:mi><mml:msup><mml:mi>B</mml:mi><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mtext> </mml:mtext><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>B</mml:mi><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:msqrt><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>B</mml:mi><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>4</mml:mn><mml:mo>⋅</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:msubsup><mml:mi>B</mml:mi><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msubsup></mml:msqrt></mml:mrow><mml:mn>2</mml:mn></mml:mfrac></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>which follows from solving a quadratic function originating from mass action kinetics combined with equilibrium assumption for the signal strength.</p><p>Simultaneously, all individual parameters (<inline-formula><mml:math id="inf8"><mml:msup><mml:mrow><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mi>*</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mi>*</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi>A</mml:mi><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mi>*</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:math></inline-formula>) per biological replicate were fitted together with the global <italic>K</italic><sub>D</sub> value. To estimate the noise level within the technical replicates we used an error model with absolute and relative errors represented by two parameters per biological replicate. With three biological replicates, this results in a total of 16 parameters that were fitted simultaneously. We utilized deterministic multistart optimization to obtain the best parameter set that minimizes deviation between model and data in terms of the negative log-likelihood. Uncertainty of the parameter of interest <italic>K</italic><sub>D</sub> is quantified using profile likelihood method (<xref ref-type="bibr" rid="bib36">Kreutz et al., 2013</xref>), which is also termed error surface plots in the literature. This fitting procedure was independently applied to each condition in order to obtain <italic>K</italic><sub>D</sub> values and corresponding uncertainties for all four conditions. Data2Dynamics Software (<xref ref-type="bibr" rid="bib56">Raue et al., 2015</xref>) used for <italic>K</italic><sub>D</sub> determination from data including biological and technical replicates is available at GitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/Data2Dynamics/d2d">https://github.com/Data2Dynamics/d2d</ext-link>, copy archived at <xref ref-type="bibr" rid="bib37">Kreutz, 2023</xref>).</p></sec><sec id="s4-9"><title>Interaction of proteins with lipid membranes</title><p>The POPC:POPS (Avanti Polar Lipids, Birmingham, AL, USA) mixture (3:1 molar ratio) in chloroform was dried in round bottom glass vials under a nitrogen stream. The dried lipid film was resuspended in liposome buffer (20 mM HEPES, 150 mM NaCl, 10% sucrose, pH 7.2) at a final concentration of 4 mM, sonified three times for 20 s with 40 s breaks (Bandelin Sonorex ultrasonic bath). Then liposomes were subjected to 10 freeze–thaw cycles and extruded through a 1-μm polypropylene membrane (Avestin, Ottawa, Canada). The size of the resulting liposomes was controlled with DLS (DynaPro NanoStar, Wyatt Technology, Santa Barbara, CA, USA). Liposomes were stored at room temperature in the dark.</p><p>The lipidprotein co-sedimentation assay was performed mostly as described previously (<xref ref-type="bibr" rid="bib73">Zozulya and Stryer, 1992</xref>). Briefly, proteins were transferred to the assay buffer. Liposomes were washed once with the assay buffer containing either 2 mM CaCl<sub>2</sub> (Ca<sup>2+</sup> condition) or 1 mM EGTA (Mg<sup>2+</sup> condition) and mixed with the protein in the respective buffer. Final lipid and protein concentrations were 1.4 mM and 10 µM, respectively. The samples were incubated for 20 min at 24°C with constant mixing and centrifuged at 17,000 × <italic>g</italic> for 15 min. The pellet was washed once with the respective buffer and resuspended in 1× reducing NuPAGE LDS sample buffer (Thermo Fisher Scientific). Samples were analysed using 4-12% NuPAGE Bis-Tris gels (Thermo Fisher Scientific).</p><p>The lipid-binding experiments were performed with three individually purified biological replicates of CHP3 and mCHP3 and respective complexes with CBD. Three technical replicates were analysed for Recoverin and mRecoverin as controls. Densitometry of protein bands was done with ImageJ (NIH). Band intensities were normalized to the Mg<sup>2+</sup> condition of the respective non-myristoylated protein.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>is an employee and shareholder of Logopharm GmbH that produces ComplexioLyte 47 used in this study</p></fn><fn fn-type="COI-statement" id="conf3"><p>is shareholder of Logopharm GmbH. The company provides ComplexioLyte reagents to academic institutions on a non-profit basis</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis, Investigation, Visualization, Writing – original draft</p></fn><fn fn-type="con" id="con3"><p>Software, Formal analysis, Validation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Validation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Validation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Investigation</p></fn><fn fn-type="con" id="con9"><p>Investigation</p></fn><fn fn-type="con" id="con10"><p>Software, Formal analysis, Supervision, Validation, Methodology</p></fn><fn fn-type="con" id="con11"><p>Supervision, Validation, Methodology</p></fn><fn fn-type="con" id="con12"><p>Supervision, Validation, Methodology</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-83868-mdarchecklist1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript. Source files have been provided for Figures 1, 4, 6, and Figure 4—figure supplement 1. Data2Dynamics Software used for EC50 and <italic>K</italic><sub>D</sub> determination is available at GitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/Data2Dynamics/d2d">https://github.com/Data2Dynamics/d2d</ext-link>, copy archived at <xref ref-type="bibr" rid="bib37">Kreutz, 2023</xref>).</p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy (CIBSS – EXC-2189 – Project ID 390939984) in the form of project funding to BW, BF, CH, CK and of CIBSS Launchpad Program Funds to EM; by the DFG through Project-ID 403222702/SFB 1381 to CH, US, and BW, through Project-ID 431984000/SFB 1453 to BF and CH, and through project-ID 278002225/RTG 2202 to CH; and by the German Ministry of Education and Research by grant EA:Sys (FKZ031L0080) to CK. We thank Prof. Willbold (Forschungszentrum Jülich, Germany) for kindly providing the pETDuet-1Δ6His_hNMT_Nef plasmid, Dr Michael Pfeffer (MS Service at University of Basel) for performing ESI mass spectrometry, and Michal Rössler (CIBSS, University of Freiburg) for supporting the artwork in <xref ref-type="fig" rid="fig7">Figures 7</xref>–<xref ref-type="fig" rid="fig8">8</xref>.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ames</surname><given-names>JB</given-names></name><name><surname>Ishima</surname><given-names>R</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Gordon</surname><given-names>JI</given-names></name><name><surname>Stryer</surname><given-names>L</given-names></name><name><surname>Ikura</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Molecular mechanics of calcium-myristoyl switches</article-title><source>Nature</source><volume>389</volume><fpage>198</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1038/38310</pub-id><pub-id pub-id-type="pmid">9296500</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ammar</surname><given-names>YB</given-names></name><name><surname>Takeda</surname><given-names>S</given-names></name><name><surname>Hisamitsu</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>H</given-names></name><name><surname>Wakabayashi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Crystal structure of CHP2 complexed with NHE1-cytosolic region and an implication for pH regulation</article-title><source>The EMBO Journal</source><volume>25</volume><fpage>2315</fpage><lpage>2325</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7601145</pub-id><pub-id pub-id-type="pmid">16710297</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrade</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Titus</surname><given-names>B</given-names></name><name><surname>Timm Pearce</surname><given-names>S</given-names></name><name><surname>Barroso</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The EF-hand Ca2+-binding protein p22 plays a role in microtubule and endoplasmic reticulum organization and dynamics with distinct Ca2+-binding requirements</article-title><source>Molecular Biology of the Cell</source><volume>15</volume><fpage>481</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1091/mbc.e03-07-0500</pub-id><pub-id pub-id-type="pmid">14657246</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bootman</surname><given-names>MD</given-names></name><name><surname>Bultynck</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Fundamentals of cellular calcium signaling: A primer</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>12</volume><elocation-id>a038802</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a038802</pub-id><pub-id pub-id-type="pmid">31427372</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braun</surname><given-names>T</given-names></name><name><surname>McIlhinney</surname><given-names>RA</given-names></name><name><surname>Vergères</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Myristoylation-dependent N-terminal cleavage of the myristoylated alanine-rich C kinase substrate (MARCKS) by cellular extracts</article-title><source>Biochimie</source><volume>82</volume><fpage>705</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1016/s0300-9084(00)01154-8</pub-id><pub-id pub-id-type="pmid">11018286</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgoyne</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The neuronal calcium-sensor proteins</article-title><source>Biochimica et Biophysica Acta</source><volume>1742</volume><fpage>59</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2004.08.008</pub-id><pub-id pub-id-type="pmid">15590056</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgoyne</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Neuronal calcium sensor proteins: generating diversity in neuronal Ca2+ signalling</article-title><source>Nature Reviews. Neuroscience</source><volume>8</volume><fpage>182</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1038/nrn2093</pub-id><pub-id pub-id-type="pmid">17311005</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgoyne</surname><given-names>RD</given-names></name><name><surname>Helassa</surname><given-names>N</given-names></name><name><surname>McCue</surname><given-names>HV</given-names></name><name><surname>Haynes</surname><given-names>LP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Calcium sensors in neuronal function and dysfunction</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>11</volume><elocation-id>a035154</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a035154</pub-id><pub-id pub-id-type="pmid">30833454</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chazin</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Relating form and function of EF-hand calcium binding proteins</article-title><source>Accounts of Chemical Research</source><volume>44</volume><fpage>171</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1021/ar100110d</pub-id><pub-id pub-id-type="pmid">21314091</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creamer</surname><given-names>TP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Calcineurin</article-title><source>Cell Communication and Signaling</source><volume>18</volume><elocation-id>137</elocation-id><pub-id pub-id-type="doi">10.1186/s12964-020-00636-4</pub-id><pub-id pub-id-type="pmid">32859215</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dannlowski</surname><given-names>U</given-names></name><name><surname>Grabe</surname><given-names>HJ</given-names></name><name><surname>Wittfeld</surname><given-names>K</given-names></name><name><surname>Klaus</surname><given-names>J</given-names></name><name><surname>Konrad</surname><given-names>C</given-names></name><name><surname>Grotegerd</surname><given-names>D</given-names></name><name><surname>Redlich</surname><given-names>R</given-names></name><name><surname>Suslow</surname><given-names>T</given-names></name><name><surname>Opel</surname><given-names>N</given-names></name><name><surname>Ohrmann</surname><given-names>P</given-names></name><name><surname>Bauer</surname><given-names>J</given-names></name><name><surname>Zwanzger</surname><given-names>P</given-names></name><name><surname>Laeger</surname><given-names>I</given-names></name><name><surname>Hohoff</surname><given-names>C</given-names></name><name><surname>Arolt</surname><given-names>V</given-names></name><name><surname>Heindel</surname><given-names>W</given-names></name><name><surname>Deppe</surname><given-names>M</given-names></name><name><surname>Domschke</surname><given-names>K</given-names></name><name><surname>Hegenscheid</surname><given-names>K</given-names></name><name><surname>Völzke</surname><given-names>H</given-names></name><name><surname>Stacey</surname><given-names>D</given-names></name><name><surname>Meyer Zu Schwabedissen</surname><given-names>H</given-names></name><name><surname>Kugel</surname><given-names>H</given-names></name><name><surname>Baune</surname><given-names>BT</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Multimodal imaging of a tescalcin (TESC)-regulating polymorphism (rs7294919)-specific effects on hippocampal gray matter structure</article-title><source>Molecular Psychiatry</source><volume>20</volume><fpage>398</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1038/mp.2014.39</pub-id><pub-id pub-id-type="pmid">24776739</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Sole</surname><given-names>F</given-names></name><name><surname>Vadnagara</surname><given-names>K</given-names></name><name><surname>Moe</surname><given-names>OW</given-names></name><name><surname>Babich</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Calcineurin homologous protein: a multifunctional Ca2+-binding protein family</article-title><source>American Journal of Physiology. Renal Physiology</source><volume>303</volume><fpage>F165</fpage><lpage>F179</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00628.2011</pub-id><pub-id pub-id-type="pmid">22189947</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Ilie</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Boucher</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>XC</given-names></name><name><surname>Orlowski</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Structure and mechanism of the human NHE1-CHP1 complex</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>3474</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-23496-z</pub-id><pub-id pub-id-type="pmid">34108458</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Eftink</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2000">2000</year><chapter-title>Intrinsic fluorescence of proteins</chapter-title><person-group person-group-type="editor"><name><surname>Lakowicz</surname><given-names>JR</given-names></name></person-group><source>Topics in Fluorescence Spectroscopy: Volume 6: Protein Fluorescence</source><publisher-loc>Boston, MA</publisher-loc><publisher-name>Springer US</publisher-name><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1007/b115628</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenberg</surname><given-names>D</given-names></name><name><surname>Schwarz</surname><given-names>E</given-names></name><name><surname>Komaromy</surname><given-names>M</given-names></name><name><surname>Wall</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Analysis of membrane and surface protein sequences with the hydrophobic moment plot</article-title><source>Journal of Molecular Biology</source><volume>179</volume><fpage>125</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/0022-2836(84)90309-7</pub-id><pub-id pub-id-type="pmid">6502707</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fontana</surname><given-names>A</given-names></name><name><surname>Polverino de Laureto</surname><given-names>P</given-names></name><name><surname>De Filippis</surname><given-names>V</given-names></name><name><surname>Scaramella</surname><given-names>E</given-names></name><name><surname>Zambonin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Probing the partly folded states of proteins by limited proteolysis</article-title><source>Folding &amp; Design</source><volume>2</volume><fpage>R17</fpage><lpage>R26</lpage><pub-id pub-id-type="doi">10.1016/S1359-0278(97)00010-2</pub-id><pub-id pub-id-type="pmid">9135978</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuchs</surname><given-names>S</given-names></name><name><surname>Hansen</surname><given-names>SC</given-names></name><name><surname>Markones</surname><given-names>M</given-names></name><name><surname>Mymrikov</surname><given-names>EV</given-names></name><name><surname>Heerklotz</surname><given-names>H</given-names></name><name><surname>Hunte</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Calcineurin B homologous protein 3 binds with high affinity to the CHP binding domain of the human sodium/proton exchanger NHE1</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>14837</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-33096-5</pub-id><pub-id pub-id-type="pmid">30287853</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaffarogullari</surname><given-names>EC</given-names></name><name><surname>Masterson</surname><given-names>LR</given-names></name><name><surname>Metcalfe</surname><given-names>EE</given-names></name><name><surname>Traaseth</surname><given-names>NJ</given-names></name><name><surname>Balatri</surname><given-names>E</given-names></name><name><surname>Musa</surname><given-names>MM</given-names></name><name><surname>Mullen</surname><given-names>D</given-names></name><name><surname>Distefano</surname><given-names>MD</given-names></name><name><surname>Veglia</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A myristoyl/phosphoserine switch controls cAMP-dependent protein kinase association to membranes</article-title><source>Journal of Molecular Biology</source><volume>411</volume><fpage>823</fpage><lpage>836</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2011.06.034</pub-id><pub-id pub-id-type="pmid">21740913</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gifford</surname><given-names>JL</given-names></name><name><surname>Walsh</surname><given-names>MP</given-names></name><name><surname>Vogel</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Structures and metal-ion-binding properties of the Ca2+-binding helix-loop-helix EF-hand motifs</article-title><source>The Biochemical Journal</source><volume>405</volume><fpage>199</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1042/BJ20070255</pub-id><pub-id pub-id-type="pmid">17590154</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gifford</surname><given-names>JL</given-names></name><name><surname>Vogel</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><chapter-title>EF-hand proteins and magnesium</chapter-title><person-group person-group-type="editor"><name><surname>Kretsinger</surname><given-names>RH</given-names></name><name><surname>Uversky</surname><given-names>VN</given-names></name><name><surname>Permyakov</surname><given-names>EA</given-names></name></person-group><source>Encyclopedia of Metalloproteins</source><publisher-name>Springer</publisher-name><fpage>775</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.1007/978-1-4614-1533-6</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glück</surname><given-names>JM</given-names></name><name><surname>Hoffmann</surname><given-names>S</given-names></name><name><surname>Koenig</surname><given-names>BW</given-names></name><name><surname>Willbold</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Single vector system for efficient N-myristoylation of recombinant proteins in <italic>E. coli</italic></article-title><source>PLOS ONE</source><volume>5</volume><elocation-id>e10081</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0010081</pub-id><pub-id pub-id-type="pmid">20404920</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Structural basis for activation of ARF GTPase: mechanisms of guanine nucleotide exchange and GTP-myristoyl switching</article-title><source>Cell</source><volume>95</volume><fpage>237</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)81754-7</pub-id><pub-id pub-id-type="pmid">9790530</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grabarek</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Insights into modulation of calcium signaling by magnesium in calmodulin, troponin C and related EF-hand proteins</article-title><source>Biochimica et Biophysica Acta</source><volume>1813</volume><fpage>913</fpage><lpage>921</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2011.01.017</pub-id><pub-id pub-id-type="pmid">21262274</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutierrez-Ford</surname><given-names>C</given-names></name><name><surname>Levay</surname><given-names>K</given-names></name><name><surname>Gomes</surname><given-names>AV</given-names></name><name><surname>Perera</surname><given-names>EM</given-names></name><name><surname>Som</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>YM</given-names></name><name><surname>Benovic</surname><given-names>JL</given-names></name><name><surname>Berkovitz</surname><given-names>GD</given-names></name><name><surname>Slepak</surname><given-names>VZ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Characterization of tescalcin, a novel EF-hand protein with a single Ca2+-binding site: metal-binding properties, localization in tissues and cells, and effect on calcineurin</article-title><source>Biochemistry</source><volume>42</volume><fpage>14553</fpage><lpage>14565</lpage><pub-id pub-id-type="doi">10.1021/bi034870f</pub-id><pub-id pub-id-type="pmid">14661968</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT</article-title><source>Nucleic Acids Symposium Series</source><volume>41</volume><fpage>95</fpage><lpage>98</lpage></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanakam</surname><given-names>F</given-names></name><name><surname>Gerisch</surname><given-names>G</given-names></name><name><surname>Lotz</surname><given-names>S</given-names></name><name><surname>Alt</surname><given-names>T</given-names></name><name><surname>Seelig</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Binding of hisactophilin I and II to lipid membranes is controlled by a pH-dependent myristoyl-histidine switch</article-title><source>Biochemistry</source><volume>35</volume><fpage>11036</fpage><lpage>11044</lpage><pub-id pub-id-type="doi">10.1021/bi960789j</pub-id><pub-id pub-id-type="pmid">8780505</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horgusluoglu-Moloch</surname><given-names>E</given-names></name><name><surname>Risacher</surname><given-names>SL</given-names></name><name><surname>Crane</surname><given-names>PK</given-names></name><name><surname>Hibar</surname><given-names>D</given-names></name><name><surname>Thompson</surname><given-names>PM</given-names></name><name><surname>Saykin</surname><given-names>AJ</given-names></name><name><surname>Nho</surname><given-names>K</given-names></name><collab>Alzheimer’s Disease Neuroimaging Initiative (ADNI)</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Genome-wide association analysis of hippocampal volume identifies enrichment of neurogenesis-related pathways</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>14498</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-50507-3</pub-id><pub-id pub-id-type="pmid">31601890</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Aramsangtienchai</surname><given-names>P</given-names></name><name><surname>Tong</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Protein lipidation: Occurrence, mechanisms, biological functions, and enabling technologies</article-title><source>Chemical Reviews</source><volume>118</volume><fpage>919</fpage><lpage>988</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.6b00750</pub-id><pub-id pub-id-type="pmid">29292991</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>YH</given-names></name><name><surname>Oh</surname><given-names>BM</given-names></name><name><surname>Uhm</surname><given-names>TG</given-names></name><name><surname>Park</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>TW</given-names></name><name><surname>Han</surname><given-names>SR</given-names></name><name><surname>Lee</surname><given-names>S-J</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>HG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tescalcin expression contributes to invasive and metastatic activity in colorectal cancer</article-title><source>Tumor Biology</source><volume>37</volume><fpage>13843</fpage><lpage>13853</lpage><pub-id pub-id-type="doi">10.1007/s13277-016-5262-0</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawasaki</surname><given-names>H</given-names></name><name><surname>Kretsinger</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Structural and functional diversity of EF-hand proteins: Evolutionary perspectives</article-title><source>Protein Science</source><volume>26</volume><fpage>1898</fpage><lpage>1920</lpage><pub-id pub-id-type="doi">10.1002/pro.3233</pub-id><pub-id pub-id-type="pmid">28707401</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>MT</given-names></name><name><surname>Brockman</surname><given-names>H</given-names></name><name><surname>Rusnak</surname><given-names>F</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Contributions of myristoylation to calcineurin structure/function</article-title><source>The Journal of Biological Chemistry</source><volume>271</volume><fpage>26517</fpage><lpage>26521</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.43.26517</pub-id><pub-id pub-id-type="pmid">8900120</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Yoo</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Kang</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Differential expression of tescalcin by modification of promoter methylation controls cell survival in gastric cancer cells</article-title><source>Oncology Reports</source><volume>41</volume><fpage>3464</fpage><lpage>3474</lpage><pub-id pub-id-type="doi">10.3892/or.2019.7099</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>TY</given-names></name><name><surname>Wakabayashi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Calcineurin B homologous protein 3 negatively regulates cardiomyocyte hypertrophy via inhibition of glycogen synthase kinase 3 phosphorylation</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>84</volume><fpage>133</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2015.04.018</pub-id><pub-id pub-id-type="pmid">25935310</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kollewe</surname><given-names>A</given-names></name><name><surname>Chubanov</surname><given-names>V</given-names></name><name><surname>Tseung</surname><given-names>FT</given-names></name><name><surname>Correia</surname><given-names>L</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>Rössig</surname><given-names>A</given-names></name><name><surname>Zierler</surname><given-names>S</given-names></name><name><surname>Haupt</surname><given-names>A</given-names></name><name><surname>Müller</surname><given-names>CS</given-names></name><name><surname>Bildl</surname><given-names>W</given-names></name><name><surname>Schulte</surname><given-names>U</given-names></name><name><surname>Nicke</surname><given-names>A</given-names></name><name><surname>Fakler</surname><given-names>B</given-names></name><name><surname>Gudermann</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The molecular appearance of native TRPM7 channel complexes identified by high-resolution proteomics</article-title><source>eLife</source><volume>10</volume><elocation-id>e68544</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.68544</pub-id><pub-id pub-id-type="pmid">34766907</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolobynina</surname><given-names>KG</given-names></name><name><surname>Solovyova</surname><given-names>VV</given-names></name><name><surname>Levay</surname><given-names>K</given-names></name><name><surname>Rizvanov</surname><given-names>AA</given-names></name><name><surname>Slepak</surname><given-names>VZ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Emerging roles of the single EF-hand Ca2+ sensor tescalcin in the regulation of gene expression, cell growth and differentiation</article-title><source>Journal of Cell Science</source><volume>129</volume><fpage>3533</fpage><lpage>3540</lpage><pub-id pub-id-type="doi">10.1242/jcs.191486</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreutz</surname><given-names>C</given-names></name><name><surname>Raue</surname><given-names>A</given-names></name><name><surname>Kaschek</surname><given-names>D</given-names></name><name><surname>Timmer</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Profile likelihood in systems biology</article-title><source>The FEBS Journal</source><volume>280</volume><fpage>2564</fpage><lpage>2571</lpage><pub-id pub-id-type="doi">10.1111/febs.12276</pub-id><pub-id pub-id-type="pmid">23581573</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Kreutz</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Data2Dynamics</data-title><version designator="swh:1:rev:9a7f501bb8def07a458d8fba463d36a04e5e8822">swh:1:rev:9a7f501bb8def07a458d8fba463d36a04e5e8822</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:6fd329e2b5d4f02e455cdfe37b491d8e159ccda5;origin=https://github.com/Data2Dynamics/d2d;visit=swh:1:snp:d3d16759a3398a418d5c924e9c65095b6267c80f;anchor=swh:1:rev:9a7f501bb8def07a458d8fba463d36a04e5e8822">https://archive.softwareheritage.org/swh:1:dir:6fd329e2b5d4f02e455cdfe37b491d8e159ccda5;origin=https://github.com/Data2Dynamics/d2d;visit=swh:1:snp:d3d16759a3398a418d5c924e9c65095b6267c80f;anchor=swh:1:rev:9a7f501bb8def07a458d8fba463d36a04e5e8822</ext-link></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krois</surname><given-names>AS</given-names></name><name><surname>Dyson</surname><given-names>HJ</given-names></name><name><surname>Wright</surname><given-names>PE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Long-range regulation of p53 DNA binding by its intrinsically disordered N-terminal transactivation domain</article-title><source>PNAS</source><volume>115</volume><fpage>E11302</fpage><lpage>E11310</lpage><pub-id pub-id-type="doi">10.1073/pnas.1814051115</pub-id><pub-id pub-id-type="pmid">30420502</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Choi</surname><given-names>SI</given-names></name><name><surname>Kim</surname><given-names>RK</given-names></name><name><surname>Cho</surname><given-names>EW</given-names></name><name><surname>Kim</surname><given-names>IG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Tescalcin/c-Src/IGF1Rβ-mediated STAT3 activation enhances cancer stemness and radioresistant properties through ALDH1</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>10711</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-29142-x</pub-id><pub-id pub-id-type="pmid">30013043</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levay</surname><given-names>K</given-names></name><name><surname>Slepak</surname><given-names>VZ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Regulation of Cop9 signalosome activity by the EF-hand Ca2+-binding protein tescalcin</article-title><source>Journal of Cell Science</source><volume>127</volume><fpage>2448</fpage><lpage>2459</lpage><pub-id pub-id-type="doi">10.1242/jcs.139592</pub-id><pub-id pub-id-type="pmid">24659803</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>QH</given-names></name><name><surname>Wang</surname><given-names>LH</given-names></name><name><surname>Lin</surname><given-names>YN</given-names></name><name><surname>Chang</surname><given-names>GQ</given-names></name><name><surname>Li</surname><given-names>HW</given-names></name><name><surname>Jin</surname><given-names>WN</given-names></name><name><surname>Hu</surname><given-names>RH</given-names></name><name><surname>Pang</surname><given-names>TX</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Nuclear accumulation of calcineurin B homologous protein 2 (CHP2) results in enhanced proliferation of tumor cells</article-title><source>Genes to Cells</source><volume>16</volume><fpage>416</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2443.2011.01497.x</pub-id><pub-id pub-id-type="pmid">21392185</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>S</given-names></name><name><surname>Fuchs</surname><given-names>S</given-names></name><name><surname>Mymrikov</surname><given-names>EV</given-names></name><name><surname>Stulz</surname><given-names>A</given-names></name><name><surname>Kaiser</surname><given-names>M</given-names></name><name><surname>Heerklotz</surname><given-names>H</given-names></name><name><surname>Hunte</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Calcium affects CHP1 and CHP2 conformation and their interaction with sodium/proton exchanger 1</article-title><source>FASEB Journal</source><volume>34</volume><fpage>3253</fpage><lpage>3266</lpage><pub-id pub-id-type="doi">10.1096/fj.201902093R</pub-id><pub-id pub-id-type="pmid">31912575</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>S</given-names></name><name><surname>Dizhoor</surname><given-names>AM</given-names></name><name><surname>Ames</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Structural diversity of neuronal calcium sensor proteins and insights for activation of retinal guanylyl cyclase by GCAP1</article-title><source>Frontiers in Molecular Neuroscience</source><volume>7</volume><elocation-id>19</elocation-id><pub-id pub-id-type="doi">10.3389/fnmol.2014.00019</pub-id><pub-id pub-id-type="pmid">24672427</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>AJ</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>LY</given-names></name><name><surname>Jiang</surname><given-names>XZ</given-names></name><name><surname>Jiang</surname><given-names>ZQ</given-names></name><name><surname>Zeng</surname><given-names>Q</given-names></name><name><surname>Yao</surname><given-names>K</given-names></name><name><surname>Xue</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Suppression of Tescalcin inhibits growth and metastasis in renal cell carcinoma via downregulating NHE1 and NF-kB signaling</article-title><source>Experimental and Molecular Pathology</source><volume>107</volume><fpage>110</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.yexmp.2018.12.004</pub-id><pub-id pub-id-type="pmid">30594602</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marty</surname><given-names>MT</given-names></name><name><surname>Baldwin</surname><given-names>AJ</given-names></name><name><surname>Marklund</surname><given-names>EG</given-names></name><name><surname>Hochberg</surname><given-names>GKA</given-names></name><name><surname>Benesch</surname><given-names>JLP</given-names></name><name><surname>Robinson</surname><given-names>CV</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Bayesian deconvolution of mass and ion mobility spectra: from binary interactions to polydisperse ensembles</article-title><source>Analytical Chemistry</source><volume>87</volume><fpage>4370</fpage><lpage>4376</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.5b00140</pub-id><pub-id pub-id-type="pmid">25799115</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFerran</surname><given-names>BW</given-names></name><name><surname>Weiss</surname><given-names>JL</given-names></name><name><surname>Burgoyne</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Neuronal Ca(2+) sensor 1. Characterization of the myristoylated protein, its cellular effects in permeabilized adrenal chromaffin cells, Ca(2+)-independent membrane association, and interaction with binding proteins, suggesting a role in rapid Ca(2+) signal transduction</article-title><source>The Journal of Biological Chemistry</source><volume>274</volume><fpage>30258</fpage><lpage>30265</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.42.30258</pub-id><pub-id pub-id-type="pmid">10514519</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishima</surname><given-names>M</given-names></name><name><surname>Wakabayashi</surname><given-names>S</given-names></name><name><surname>Kojima</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Solution structure of the cytoplasmic region of Na+/H+ exchanger 1 complexed with essential cofactor calcineurin B homologous protein 1</article-title><source>The Journal of Biological Chemistry</source><volume>282</volume><fpage>2741</fpage><lpage>2751</lpage><pub-id pub-id-type="doi">10.1074/jbc.M604092200</pub-id><pub-id pub-id-type="pmid">17050540</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naoe</surname><given-names>Y</given-names></name><name><surname>Arita</surname><given-names>K</given-names></name><name><surname>Hashimoto</surname><given-names>H</given-names></name><name><surname>Kanazawa</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Shimizu</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Structural characterization of calcineurin B homologous protein 1</article-title><source>The Journal of Biological Chemistry</source><volume>280</volume><fpage>32372</fpage><lpage>32378</lpage><pub-id pub-id-type="doi">10.1074/jbc.M503390200</pub-id><pub-id pub-id-type="pmid">15987692</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>MR</given-names></name><name><surname>Chazin</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>An interaction-based analysis of calcium-induced conformational changes in Ca2+ sensor proteins</article-title><source>Protein Science</source><volume>7</volume><fpage>270</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1002/pro.5560070206</pub-id><pub-id pub-id-type="pmid">9521102</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niesen</surname><given-names>FH</given-names></name><name><surname>Berglund</surname><given-names>H</given-names></name><name><surname>Vedadi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability</article-title><source>Nature Protocols</source><volume>2</volume><fpage>2212</fpage><lpage>2221</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.321</pub-id><pub-id pub-id-type="pmid">17853878</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Callaghan</surname><given-names>DW</given-names></name><name><surname>Hasdemir</surname><given-names>B</given-names></name><name><surname>Leighton</surname><given-names>M</given-names></name><name><surname>Burgoyne</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Residues within the myristoylation motif determine intracellular targeting of the neuronal Ca2+ sensor protein KChIP1 to post-ER transport vesicles and traffic of Kv4 K+ channels</article-title><source>Journal of Cell Science</source><volume>116</volume><fpage>4833</fpage><lpage>4845</lpage><pub-id pub-id-type="doi">10.1242/jcs.00803</pub-id><pub-id pub-id-type="pmid">14600268</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Callaghan</surname><given-names>DW</given-names></name><name><surname>Burgoyne</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Identification of residues that determine the absence of a Ca(2+)/myristoyl switch in neuronal calcium sensor-1</article-title><source>The Journal of Biological Chemistry</source><volume>279</volume><fpage>14347</fpage><lpage>14354</lpage><pub-id pub-id-type="doi">10.1074/jbc.M310152200</pub-id><pub-id pub-id-type="pmid">14726528</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>T</given-names></name><name><surname>Hisamitsu</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>H</given-names></name><name><surname>Shigekawa</surname><given-names>M</given-names></name><name><surname>Wakabayashi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Role of calcineurin B homologous protein in pH regulation by the Na+/H+ exchanger 1: tightly bound Ca2+ ions as important structural elements</article-title><source>Biochemistry</source><volume>43</volume><fpage>3628</fpage><lpage>3636</lpage><pub-id pub-id-type="doi">10.1021/bi0360004</pub-id><pub-id pub-id-type="pmid">15035633</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>SF</given-names></name><name><surname>Counillon</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The SLC9A-C Mammalian Na(+)/H(+) Exchanger Family: Molecules, Mechanisms, and Physiology</article-title><source>Physiological Reviews</source><volume>99</volume><fpage>2015</fpage><lpage>2113</lpage><pub-id pub-id-type="doi">10.1152/physrev.00028.2018</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perera</surname><given-names>EM</given-names></name><name><surname>Martin</surname><given-names>H</given-names></name><name><surname>Seeherunvong</surname><given-names>T</given-names></name><name><surname>Kos</surname><given-names>L</given-names></name><name><surname>Hughes</surname><given-names>IA</given-names></name><name><surname>Hawkins</surname><given-names>JR</given-names></name><name><surname>Berkovitz</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Tescalcin, a novel gene encoding a putative EF-hand Ca(2+)-binding protein, Col9a3, and renin are expressed in the mouse testis during the early stages of gonadal differentiation</article-title><source>Endocrinology</source><volume>142</volume><fpage>455</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1210/endo.142.1.7882</pub-id><pub-id pub-id-type="pmid">11145610</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raue</surname><given-names>A</given-names></name><name><surname>Steiert</surname><given-names>B</given-names></name><name><surname>Schelker</surname><given-names>M</given-names></name><name><surname>Kreutz</surname><given-names>C</given-names></name><name><surname>Maiwald</surname><given-names>T</given-names></name><name><surname>Hass</surname><given-names>H</given-names></name><name><surname>Vanlier</surname><given-names>J</given-names></name><name><surname>Tönsing</surname><given-names>C</given-names></name><name><surname>Adlung</surname><given-names>L</given-names></name><name><surname>Engesser</surname><given-names>R</given-names></name><name><surname>Mader</surname><given-names>W</given-names></name><name><surname>Heinemann</surname><given-names>T</given-names></name><name><surname>Hasenauer</surname><given-names>J</given-names></name><name><surname>Schilling</surname><given-names>M</given-names></name><name><surname>Höfer</surname><given-names>T</given-names></name><name><surname>Klipp</surname><given-names>E</given-names></name><name><surname>Theis</surname><given-names>F</given-names></name><name><surname>Klingmüller</surname><given-names>U</given-names></name><name><surname>Schöberl</surname><given-names>B</given-names></name><name><surname>Timmer</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Data2Dynamics: a modeling environment tailored to parameter estimation in dynamical systems</article-title><source>Bioinformatics</source><volume>31</volume><fpage>3558</fpage><lpage>3560</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btv405</pub-id><pub-id pub-id-type="pmid">26142188</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roderick</surname><given-names>HL</given-names></name><name><surname>Cook</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Ca2+ signalling checkpoints in cancer: remodelling Ca2+ for cancer cell proliferation and survival</article-title><source>Nature Reviews. Cancer</source><volume>8</volume><fpage>361</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1038/nrc2374</pub-id><pub-id pub-id-type="pmid">18432251</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheuermann</surname><given-names>TH</given-names></name><name><surname>Padrick</surname><given-names>SB</given-names></name><name><surname>Gardner</surname><given-names>KH</given-names></name><name><surname>Brautigam</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>On the acquisition and analysis of microscale thermophoresis data</article-title><source>Analytical Biochemistry</source><volume>496</volume><fpage>79</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2015.12.013</pub-id><pub-id pub-id-type="pmid">26739938</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwenk</surname><given-names>J</given-names></name><name><surname>Harmel</surname><given-names>N</given-names></name><name><surname>Brechet</surname><given-names>A</given-names></name><name><surname>Zolles</surname><given-names>G</given-names></name><name><surname>Berkefeld</surname><given-names>H</given-names></name><name><surname>Müller</surname><given-names>CS</given-names></name><name><surname>Bildl</surname><given-names>W</given-names></name><name><surname>Baehrens</surname><given-names>D</given-names></name><name><surname>Hüber</surname><given-names>B</given-names></name><name><surname>Kulik</surname><given-names>A</given-names></name><name><surname>Klöcker</surname><given-names>N</given-names></name><name><surname>Schulte</surname><given-names>U</given-names></name><name><surname>Fakler</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>High-resolution proteomics unravel architecture and molecular diversity of native AMPA receptor complexes</article-title><source>Neuron</source><volume>74</volume><fpage>621</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2012.03.034</pub-id><pub-id pub-id-type="pmid">22632720</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staby</surname><given-names>L</given-names></name><name><surname>Due</surname><given-names>AD</given-names></name><name><surname>Kunze</surname><given-names>MBA</given-names></name><name><surname>Jørgensen</surname><given-names>MLM</given-names></name><name><surname>Skriver</surname><given-names>K</given-names></name><name><surname>Kragelund</surname><given-names>BB</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Flanking Disorder of the Folded αα-Hub Domain from Radical Induced Cell Death1 Affects Transcription Factor Binding by Ensemble Redistribution</article-title><source>Journal of Molecular Biology</source><volume>433</volume><elocation-id>167320</elocation-id><pub-id pub-id-type="doi">10.1016/j.jmb.2021.167320</pub-id><pub-id pub-id-type="pmid">34687712</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>JL</given-names></name><name><surname>Medland</surname><given-names>SE</given-names></name><name><surname>Vasquez</surname><given-names>AA</given-names></name><name><surname>Hibar</surname><given-names>DP</given-names></name><name><surname>Senstad</surname><given-names>RE</given-names></name><name><surname>Winkler</surname><given-names>AM</given-names></name><name><surname>Toro</surname><given-names>R</given-names></name><name><surname>Appel</surname><given-names>K</given-names></name><name><surname>Bartecek</surname><given-names>R</given-names></name><name><surname>Bergmann</surname><given-names>Ø</given-names></name><name><surname>Bernard</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>AA</given-names></name><name><surname>Cannon</surname><given-names>DM</given-names></name><name><surname>Chakravarty</surname><given-names>MM</given-names></name><name><surname>Christoforou</surname><given-names>A</given-names></name><name><surname>Domin</surname><given-names>M</given-names></name><name><surname>Grimm</surname><given-names>O</given-names></name><name><surname>Hollinshead</surname><given-names>M</given-names></name><name><surname>Holmes</surname><given-names>AJ</given-names></name><name><surname>Homuth</surname><given-names>G</given-names></name><name><surname>Hottenga</surname><given-names>JJ</given-names></name><name><surname>Langan</surname><given-names>C</given-names></name><name><surname>Lopez</surname><given-names>LM</given-names></name><name><surname>Hansell</surname><given-names>NK</given-names></name><name><surname>Hwang</surname><given-names>KS</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Laje</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>PH</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Loth</surname><given-names>E</given-names></name><name><surname>Lourdusamy</surname><given-names>A</given-names></name><name><surname>Mattingsdal</surname><given-names>M</given-names></name><name><surname>Mohnke</surname><given-names>S</given-names></name><name><surname>Maniega</surname><given-names>SM</given-names></name><name><surname>Nho</surname><given-names>K</given-names></name><name><surname>Nugent</surname><given-names>AC</given-names></name><name><surname>O’Brien</surname><given-names>C</given-names></name><name><surname>Papmeyer</surname><given-names>M</given-names></name><name><surname>Pütz</surname><given-names>B</given-names></name><name><surname>Ramasamy</surname><given-names>A</given-names></name><name><surname>Rasmussen</surname><given-names>J</given-names></name><name><surname>Rijpkema</surname><given-names>M</given-names></name><name><surname>Risacher</surname><given-names>SL</given-names></name><name><surname>Roddey</surname><given-names>JC</given-names></name><name><surname>Rose</surname><given-names>EJ</given-names></name><name><surname>Ryten</surname><given-names>M</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Sprooten</surname><given-names>E</given-names></name><name><surname>Strengman</surname><given-names>E</given-names></name><name><surname>Teumer</surname><given-names>A</given-names></name><name><surname>Trabzuni</surname><given-names>D</given-names></name><name><surname>Turner</surname><given-names>J</given-names></name><name><surname>van Eijk</surname><given-names>K</given-names></name><name><surname>van Erp</surname><given-names>TGM</given-names></name><name><surname>van Tol</surname><given-names>MJ</given-names></name><name><surname>Wittfeld</surname><given-names>K</given-names></name><name><surname>Wolf</surname><given-names>C</given-names></name><name><surname>Woudstra</surname><given-names>S</given-names></name><name><surname>Aleman</surname><given-names>A</given-names></name><name><surname>Alhusaini</surname><given-names>S</given-names></name><name><surname>Almasy</surname><given-names>L</given-names></name><name><surname>Binder</surname><given-names>EB</given-names></name><name><surname>Brohawn</surname><given-names>DG</given-names></name><name><surname>Cantor</surname><given-names>RM</given-names></name><name><surname>Carless</surname><given-names>MA</given-names></name><name><surname>Corvin</surname><given-names>A</given-names></name><name><surname>Czisch</surname><given-names>M</given-names></name><name><surname>Curran</surname><given-names>JE</given-names></name><name><surname>Davies</surname><given-names>G</given-names></name><name><surname>de Almeida</surname><given-names>MAA</given-names></name><name><surname>Delanty</surname><given-names>N</given-names></name><name><surname>Depondt</surname><given-names>C</given-names></name><name><surname>Duggirala</surname><given-names>R</given-names></name><name><surname>Dyer</surname><given-names>TD</given-names></name><name><surname>Erk</surname><given-names>S</given-names></name><name><surname>Fagerness</surname><given-names>J</given-names></name><name><surname>Fox</surname><given-names>PT</given-names></name><name><surname>Freimer</surname><given-names>NB</given-names></name><name><surname>Gill</surname><given-names>M</given-names></name><name><surname>Göring</surname><given-names>HHH</given-names></name><name><surname>Hagler</surname><given-names>DJ</given-names></name><name><surname>Hoehn</surname><given-names>D</given-names></name><name><surname>Holsboer</surname><given-names>F</given-names></name><name><surname>Hoogman</surname><given-names>M</given-names></name><name><surname>Hosten</surname><given-names>N</given-names></name><name><surname>Jahanshad</surname><given-names>N</given-names></name><name><surname>Johnson</surname><given-names>MP</given-names></name><name><surname>Kasperaviciute</surname><given-names>D</given-names></name><name><surname>Kent</surname><given-names>JW</given-names></name><name><surname>Kochunov</surname><given-names>P</given-names></name><name><surname>Lancaster</surname><given-names>JL</given-names></name><name><surname>Lawrie</surname><given-names>SM</given-names></name><name><surname>Liewald</surname><given-names>DC</given-names></name><name><surname>Mandl</surname><given-names>R</given-names></name><name><surname>Matarin</surname><given-names>M</given-names></name><name><surname>Mattheisen</surname><given-names>M</given-names></name><name><surname>Meisenzahl</surname><given-names>E</given-names></name><name><surname>Melle</surname><given-names>I</given-names></name><name><surname>Moses</surname><given-names>EK</given-names></name><name><surname>Mühleisen</surname><given-names>TW</given-names></name><name><surname>Nauck</surname><given-names>M</given-names></name><name><surname>Nöthen</surname><given-names>MM</given-names></name><name><surname>Olvera</surname><given-names>RL</given-names></name><name><surname>Pandolfo</surname><given-names>M</given-names></name><name><surname>Pike</surname><given-names>GB</given-names></name><name><surname>Puls</surname><given-names>R</given-names></name><name><surname>Reinvang</surname><given-names>I</given-names></name><name><surname>Rentería</surname><given-names>ME</given-names></name><name><surname>Rietschel</surname><given-names>M</given-names></name><name><surname>Roffman</surname><given-names>JL</given-names></name><name><surname>Royle</surname><given-names>NA</given-names></name><name><surname>Rujescu</surname><given-names>D</given-names></name><name><surname>Savitz</surname><given-names>J</given-names></name><name><surname>Schnack</surname><given-names>HG</given-names></name><name><surname>Schnell</surname><given-names>K</given-names></name><name><surname>Seiferth</surname><given-names>N</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Steen</surname><given-names>VM</given-names></name><name><surname>Valdés Hernández</surname><given-names>MC</given-names></name><name><surname>Van den Heuvel</surname><given-names>M</given-names></name><name><surname>van der Wee</surname><given-names>NJ</given-names></name><name><surname>Van Haren</surname><given-names>NEM</given-names></name><name><surname>Veltman</surname><given-names>JA</given-names></name><name><surname>Völzke</surname><given-names>H</given-names></name><name><surname>Walker</surname><given-names>R</given-names></name><name><surname>Westlye</surname><given-names>LT</given-names></name><name><surname>Whelan</surname><given-names>CD</given-names></name><name><surname>Agartz</surname><given-names>I</given-names></name><name><surname>Boomsma</surname><given-names>DI</given-names></name><name><surname>Cavalleri</surname><given-names>GL</given-names></name><name><surname>Dale</surname><given-names>AM</given-names></name><name><surname>Djurovic</surname><given-names>S</given-names></name><name><surname>Drevets</surname><given-names>WC</given-names></name><name><surname>Hagoort</surname><given-names>P</given-names></name><name><surname>Hall</surname><given-names>J</given-names></name><name><surname>Heinz</surname><given-names>A</given-names></name><name><surname>Jack</surname><given-names>CR</given-names></name><name><surname>Foroud</surname><given-names>TM</given-names></name><name><surname>Le Hellard</surname><given-names>S</given-names></name><name><surname>Macciardi</surname><given-names>F</given-names></name><name><surname>Montgomery</surname><given-names>GW</given-names></name><name><surname>Poline</surname><given-names>JB</given-names></name><name><surname>Porteous</surname><given-names>DJ</given-names></name><name><surname>Sisodiya</surname><given-names>SM</given-names></name><name><surname>Starr</surname><given-names>JM</given-names></name><name><surname>Sussmann</surname><given-names>J</given-names></name><name><surname>Toga</surname><given-names>AW</given-names></name><name><surname>Veltman</surname><given-names>DJ</given-names></name><name><surname>Walter</surname><given-names>H</given-names></name><name><surname>Weiner</surname><given-names>MW</given-names></name><collab>EPIGEN Consortium</collab><collab>IMAGEN Consortium</collab><collab>Saguenay Youth Study Group</collab><name><surname>Bis</surname><given-names>JC</given-names></name><name><surname>Ikram</surname><given-names>MA</given-names></name><name><surname>Smith</surname><given-names>AV</given-names></name><name><surname>Gudnason</surname><given-names>V</given-names></name><name><surname>Tzourio</surname><given-names>C</given-names></name><name><surname>Vernooij</surname><given-names>MW</given-names></name><name><surname>Launer</surname><given-names>LJ</given-names></name><name><surname>DeCarli</surname><given-names>C</given-names></name><name><surname>Seshadri</surname><given-names>S</given-names></name><collab>Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium</collab><name><surname>Andreassen</surname><given-names>OA</given-names></name><name><surname>Apostolova</surname><given-names>LG</given-names></name><name><surname>Bastin</surname><given-names>ME</given-names></name><name><surname>Blangero</surname><given-names>J</given-names></name><name><surname>Brunner</surname><given-names>HG</given-names></name><name><surname>Buckner</surname><given-names>RL</given-names></name><name><surname>Cichon</surname><given-names>S</given-names></name><name><surname>Coppola</surname><given-names>G</given-names></name><name><surname>de Zubicaray</surname><given-names>GI</given-names></name><name><surname>Deary</surname><given-names>IJ</given-names></name><name><surname>Donohoe</surname><given-names>G</given-names></name><name><surname>de Geus</surname><given-names>EJC</given-names></name><name><surname>Espeseth</surname><given-names>T</given-names></name><name><surname>Fernández</surname><given-names>G</given-names></name><name><surname>Glahn</surname><given-names>DC</given-names></name><name><surname>Grabe</surname><given-names>HJ</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Hulshoff Pol</surname><given-names>HE</given-names></name><name><surname>Jenkinson</surname><given-names>M</given-names></name><name><surname>Kahn</surname><given-names>RS</given-names></name><name><surname>McDonald</surname><given-names>C</given-names></name><name><surname>McIntosh</surname><given-names>AM</given-names></name><name><surname>McMahon</surname><given-names>FJ</given-names></name><name><surname>McMahon</surname><given-names>KL</given-names></name><name><surname>Meyer-Lindenberg</surname><given-names>A</given-names></name><name><surname>Morris</surname><given-names>DW</given-names></name><name><surname>Müller-Myhsok</surname><given-names>B</given-names></name><name><surname>Nichols</surname><given-names>TE</given-names></name><name><surname>Ophoff</surname><given-names>RA</given-names></name><name><surname>Paus</surname><given-names>T</given-names></name><name><surname>Pausova</surname><given-names>Z</given-names></name><name><surname>Penninx</surname><given-names>BW</given-names></name><name><surname>Potkin</surname><given-names>SG</given-names></name><name><surname>Sämann</surname><given-names>PG</given-names></name><name><surname>Saykin</surname><given-names>AJ</given-names></name><name><surname>Schumann</surname><given-names>G</given-names></name><name><surname>Smoller</surname><given-names>JW</given-names></name><name><surname>Wardlaw</surname><given-names>JM</given-names></name><name><surname>Weale</surname><given-names>ME</given-names></name><name><surname>Martin</surname><given-names>NG</given-names></name><name><surname>Franke</surname><given-names>B</given-names></name><name><surname>Wright</surname><given-names>MJ</given-names></name><name><surname>Thompson</surname><given-names>PM</given-names></name><collab>Enhancing Neuro Imaging Genetics through Meta-Analysis Consortium</collab></person-group><year iso-8601-date="2012">2012</year><article-title>Identification of common variants associated with human hippocampal and intracranial volumes</article-title><source>Nature Genetics</source><volume>44</volume><fpage>552</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1038/ng.2250</pub-id><pub-id pub-id-type="pmid">22504417</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Umekawa</surname><given-names>H</given-names></name><name><surname>Ohmura</surname><given-names>T</given-names></name><name><surname>Hidaka</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Calcium-dependent hydrophobic chromatography of calmodulin, S-100 protein and troponin-C</article-title><source>Biochimica et Biophysica Acta</source><volume>787</volume><fpage>158</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/0167-4838(84)90075-x</pub-id><pub-id pub-id-type="pmid">6733116</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teilum</surname><given-names>K</given-names></name><name><surname>Olsen</surname><given-names>JG</given-names></name><name><surname>Kragelund</surname><given-names>BB</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Functional aspects of protein flexibility</article-title><source>Cellular and Molecular Life Sciences</source><volume>66</volume><fpage>2231</fpage><lpage>2247</lpage><pub-id pub-id-type="doi">10.1007/s00018-009-0014-6</pub-id><pub-id pub-id-type="pmid">19308324</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timm</surname><given-names>S</given-names></name><name><surname>Titus</surname><given-names>B</given-names></name><name><surname>Bernd</surname><given-names>K</given-names></name><name><surname>Barroso</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>The EF-hand Ca(2+)-binding protein p22 associates with microtubules in an N-myristoylation-dependent manner</article-title><source>Molecular Biology of the Cell</source><volume>10</volume><fpage>3473</fpage><lpage>3488</lpage><pub-id pub-id-type="doi">10.1091/mbc.10.10.3473</pub-id><pub-id pub-id-type="pmid">10512881</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varadi</surname><given-names>M</given-names></name><name><surname>Anyango</surname><given-names>S</given-names></name><name><surname>Deshpande</surname><given-names>M</given-names></name><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>Natassia</surname><given-names>C</given-names></name><name><surname>Yordanova</surname><given-names>G</given-names></name><name><surname>Yuan</surname><given-names>D</given-names></name><name><surname>Stroe</surname><given-names>O</given-names></name><name><surname>Wood</surname><given-names>G</given-names></name><name><surname>Laydon</surname><given-names>A</given-names></name><name><surname>Žídek</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>Tunyasuvunakool</surname><given-names>K</given-names></name><name><surname>Petersen</surname><given-names>S</given-names></name><name><surname>Jumper</surname><given-names>J</given-names></name><name><surname>Clancy</surname><given-names>E</given-names></name><name><surname>Green</surname><given-names>R</given-names></name><name><surname>Vora</surname><given-names>A</given-names></name><name><surname>Lutfi</surname><given-names>M</given-names></name><name><surname>Figurnov</surname><given-names>M</given-names></name><name><surname>Cowie</surname><given-names>A</given-names></name><name><surname>Hobbs</surname><given-names>N</given-names></name><name><surname>Kohli</surname><given-names>P</given-names></name><name><surname>Kleywegt</surname><given-names>G</given-names></name><name><surname>Birney</surname><given-names>E</given-names></name><name><surname>Hassabis</surname><given-names>D</given-names></name><name><surname>Velankar</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models</article-title><source>Nucleic Acids Research</source><volume>50</volume><fpage>D439</fpage><lpage>D444</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab1061</pub-id><pub-id pub-id-type="pmid">34791371</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viereck</surname><given-names>J</given-names></name><name><surname>Bührke</surname><given-names>A</given-names></name><name><surname>Foinquinos</surname><given-names>A</given-names></name><name><surname>Chatterjee</surname><given-names>S</given-names></name><name><surname>Kleeberger</surname><given-names>JA</given-names></name><name><surname>Xiao</surname><given-names>K</given-names></name><name><surname>Janssen-Peters</surname><given-names>H</given-names></name><name><surname>Batkai</surname><given-names>S</given-names></name><name><surname>Ramanujam</surname><given-names>D</given-names></name><name><surname>Kraft</surname><given-names>T</given-names></name><name><surname>Cebotari</surname><given-names>S</given-names></name><name><surname>Gueler</surname><given-names>F</given-names></name><name><surname>Beyer</surname><given-names>AM</given-names></name><name><surname>Schmitz</surname><given-names>J</given-names></name><name><surname>Bräsen</surname><given-names>JH</given-names></name><name><surname>Schmitto</surname><given-names>JD</given-names></name><name><surname>Gyöngyösi</surname><given-names>M</given-names></name><name><surname>Löser</surname><given-names>A</given-names></name><name><surname>Hirt</surname><given-names>MN</given-names></name><name><surname>Eschenhagen</surname><given-names>T</given-names></name><name><surname>Engelhardt</surname><given-names>S</given-names></name><name><surname>Bär</surname><given-names>C</given-names></name><name><surname>Thum</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy</article-title><source>European Heart Journal</source><volume>41</volume><fpage>3462</fpage><lpage>3474</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehaa519</pub-id><pub-id pub-id-type="pmid">32657324</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vivian</surname><given-names>JT</given-names></name><name><surname>Callis</surname><given-names>PR</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Mechanisms of tryptophan fluorescence shifts in proteins</article-title><source>Biophysical Journal</source><volume>80</volume><fpage>2093</fpage><lpage>2109</lpage><pub-id pub-id-type="doi">10.1016/S0006-3495(01)76183-8</pub-id><pub-id pub-id-type="pmid">11325713</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vladimirov</surname><given-names>VI</given-names></name><name><surname>Baksheeva</surname><given-names>VE</given-names></name><name><surname>Mikhailova</surname><given-names>IV</given-names></name><name><surname>Ismailov</surname><given-names>RG</given-names></name><name><surname>Litus</surname><given-names>EA</given-names></name><name><surname>Tikhomirova</surname><given-names>NK</given-names></name><name><surname>Nazipova</surname><given-names>AA</given-names></name><name><surname>Permyakov</surname><given-names>SE</given-names></name><name><surname>Zernii</surname><given-names>EY</given-names></name><name><surname>Zinchenko</surname><given-names>DV</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A Novel Approach to Bacterial Expression and Purification of Myristoylated Forms of Neuronal Calcium Sensor Proteins</article-title><source>Biomolecules</source><volume>10</volume><elocation-id>1025</elocation-id><pub-id pub-id-type="doi">10.3390/biom10071025</pub-id><pub-id pub-id-type="pmid">32664359</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Lee</surname><given-names>EY</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Expression and reconstitution of calcineurin A and B subunits</article-title><source>Biochemistry and Molecular Biology International</source><volume>41</volume><fpage>169</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1080/15216549700201171</pub-id><pub-id pub-id-type="pmid">9043646</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>SA</given-names></name><name><surname>Klee</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Low affinity Ca2+-binding sites of calcineurin B mediate conformational changes in calcineurin A</article-title><source>Biochemistry</source><volume>39</volume><fpage>16147</fpage><lpage>16154</lpage><pub-id pub-id-type="doi">10.1021/bi001321q</pub-id><pub-id pub-id-type="pmid">11123943</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>ZH</given-names></name><name><surname>Ying</surname><given-names>MD</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>QJ</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>N-myristoylation: from cell biology to translational medicine</article-title><source>Acta Pharmacologica Sinica</source><volume>41</volume><fpage>1005</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1038/s41401-020-0388-4</pub-id><pub-id pub-id-type="pmid">32203082</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaun</surname><given-names>HC</given-names></name><name><surname>Shrier</surname><given-names>A</given-names></name><name><surname>Orlowski</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>N-myristoylation and Ca2+ binding of calcineurin B homologous protein CHP3 are required to enhance Na+/H+ exchanger NHE1 half-life and activity at the plasma membrane</article-title><source>The Journal of Biological Chemistry</source><volume>287</volume><fpage>36883</fpage><lpage>36895</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.394700</pub-id><pub-id pub-id-type="pmid">22984264</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zozulya</surname><given-names>S</given-names></name><name><surname>Stryer</surname><given-names>L</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Calcium-myristoyl protein switch</article-title><source>PNAS</source><volume>89</volume><fpage>11569</fpage><lpage>11573</lpage><pub-id pub-id-type="doi">10.1073/pnas.89.23.11569</pub-id><pub-id pub-id-type="pmid">1454850</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83868.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lemieux</surname><given-names>M Joanne</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0160cpw27</institution-id><institution>University of Alberta</institution></institution-wrap><country>Canada</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.09.23.509142" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.09.23.509142"/></front-stub><body><p>In this work, the authors provide important mechanistic insights into how the intracellular effector protein Calcineurin B homologous protein 3 (CHP3) can be regulated in a calcium-independent manner to expose its lipid membrane binding site. Compelling evidence demonstrates a binding partner protein (NHE1) triggers a conformation change and exposure of the myristoyl group in CHP3 resulting in membrane association. This provides mechanistic insight into the signalling mechanisms achieved by CHP3 in a target-binding dependent manner, which will be of broad scientific interest.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83868.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Lemieux</surname><given-names>M Joanne</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0160cpw27</institution-id><institution>University of Alberta</institution></institution-wrap><country>Canada</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.09.23.509142">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.09.23.509142v2">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Conformational dynamics and target-dependent myristoyl switch of calcineurin B homologous protein 3&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Richard Aldrich as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>The manuscript has been improved but there are some remaining issues that need to be addressed, as outlined below:</p><p>In particular, please address the implications of Ca<sup>2+</sup> binding affinities of the CHP proteins to the physiological concentrations of Ca<sup>2+</sup> (reviewer #1). Enhanced descriptions of the state of the protein would be helpful (see reviewer #3). Reviewer 2 provides many suggestions for improvement to the submitted manuscript, many of which I think can be easily addressed.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Please address the implications of Ca<sup>2+</sup> binding affinities of the CHP proteins to the physiological concentrations of Ca<sup>2+</sup>. Please use submicromolar-free Ca<sup>2+</sup> in all experiments.</p><p>Have you considered the effect of the poly His tail of the CBD peptide on binding to CHP3 and ions?</p><p>What is the stoichiometry of CBD binding to CHP3?</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Several of the EF-hand calcium-binding proteins are myristoylated and target membranes, and the presence of calcium-binding to induce conformational switches that unleashes a myristoyl chain has been shown in some proteins e.g. recoverin. For others, e.g. NCS1, a lack of a calcium-myristoyl switch seems to be the currently accepted mechanism. The manuscript by Becker and co-workers addresses the important question of how the myristoylated calcium-binding EF-hand protein CHP3 is regulated by ion-binding, and how binding of one of its targets, the sodium exchange NHE1 (or a peptide thereof) impacts membrane binding. The manuscript is very well written, and the data are presented in a logical way. The conclusion of a novel mechanism – a target-dependent myristoyl switch seems largely warranted by the data. There are certain wordings and conclusions that would benefit from a more precise language (or down toning) and some additional controls, and I find the discussion lengthy and repetitive to the introduction and result section and would have wished for a broader discussion putting the data in perspective for the function of NHE1 and other ligand-dependent switches. Addressing the below points would increase the value of the work and the applicability of its finding. In no prioritized order, I suggest the following:</p><p>The model and the title &quot;target-dependent&quot; suggest to me that not all targets may induce the switch and that it depends on which target it is bound to. However, only one target has been investigated. Perhaps the more correct term would be target-binding myristoyl switch. And – on that note, how is this mechanism different from the ligand-dependent myristoyl switch previously described and mentioned by the authors? This is not clear from the discussion. Some of the myristoylated calcium-binding EF-hand proteins do not have a calcium-myristoyl switch, e.g. NCS1 and other, are there any correlation between the number of calcium-bound ions and the type of switch? A more thorough discussion on this part is needed.</p><p>The claim that the tryptophan moves from a more hydrophobic into solvent exposure cannot be concluded from the intensities alone. The induced dipole in the excited state interacts with the surroundings through dipole-dipole interactions and thus a wavelength shift is expected from hydrophobic (lower wavelength) to solvent (higher wavelength). Please include these data and show the full spectra.</p><p>Were the melting curves measured by nanoDSF reversible? If not, these are apparent Tms. Can anything be inferred from the slopes (change in enthalpy) upon unfolding? If the structures are different these should be different too.</p><p>For typsinolysis, what is the coverage? Are there equally dispersed lysines/arginines across the sequence or are there silent regions not captured by this technique? It may be one reason why the nanoDSF data is not correlating with the stability measurements. However, a more detailed analysis of the gels in the supplement data and in the main figure, reveals additional bands for the mCHP3 around 15kDa (3 bands instead of 2) and below 10kDa (3 bands instead of 2) that are not present in the CHP3. These bands would be relevant to analyze. I disagree with the conclusion that by binding the peptide, there are substantial structural changes, the data can only show a lack of cleavage, which may be caused by coverage by binding, and stabilization by binding (and here it would be good to correlate to the nanoDSF data). The use of the word conformation dynamics is not appropriate, no kinetics have been measured, use instead conformational states.</p><p>The two-fold difference in affinity between CHP3 and mCHP3 for CBD is small, and thus one could argue that this is insignificant. However, it has a resemblance to some of the works on the disordered flanking regions of folded proteins that dynamically occupy a binding site in the folded domain (see e.g. works on RST and p53 with tails PMID: 34687712 and PMID: 30420502) – similar effect were seen. Would be a good addition to the discussion.</p><p>The discussion is lengthy and not forward-looking. The entire first paragraph is mostly a repetition of the introduction. It would have been appropriate to include other already mentions points above as well as a reflection of how the other calcium-binding sensitive partners to NHE1 (calmodulin and calcineurin) and the membrane interaction of NHE1 would jointly organize NHE1 at the membrane.</p><p>In the discussion, it is concluded that Ca<sup>2+</sup> induced higher flexibility. How is this conclusion reached? The same pattern of peptide cleavage is reached, and the protein is destabilized, which could be due to a different conformation as also probed with the hydrophobicity assay. It is not necessarily more flexible. Please elaborate on this to make the argumentation clearer or remove it from the discussion if not fully supported. Also, in the discussion, it is suggested that the conformation of the N-terminal lobe is affected, which data supports this? How can this be inferred from the presented data? It is also indicated in Figure 7.</p><p>The change in the amount of CHP3 in the liposome fraction upon CBD binding is very interesting and suggests that the myristoyl group and the CDB act cooperatively. Are there any relevant exposed residues on the exposed side of the bound CDB that can explain this? Lysine residues or hydrophobic residues? It would be good to have an AlphaFold2 structure of the complex to help address this.</p><p>The 3 remaining EF-hands appear not to bind calcium, where are they mutated, and which properties do they then have? Please include.</p><p>Figures</p><p>Figure 1 – it appears for both proteins that a fraction of dimers elutes as well to the left of the main peak. Please comment.</p><p>Figure 4 – relevant to indicate the potential coverage (Ks and Rs in the sequence) and not just the two where you see cleavage. Aldo the additional bands on the mCHP3 should be acknowledged.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>The description of the limited proteolysis experiment would benefit from additional detail. E.g., how many trypsin sites are in CBD? Is the stoichiometry of CBD:CHP3 1:1 or is an excess of CBD added? In the case of the latter, an experiment to determine whether CBD inhibits trypsin may be considered. Admittingly, this is unlikely to be the case, but it would further strengthen the claim of CBD-mediated stabilization.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83868.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>The manuscript has been improved but there are some remaining issues that need to be addressed, as outlined below:</p><p>In particular, please address the implications of Ca<sup>2+</sup> binding affinities of the CHP proteins to the physiological concentrations of Ca<sup>2+</sup> (reviewer #1). Enhanced descriptions of the state of the protein would be helpful (see reviewer #3). Reviewer 2 provides many suggestions for improvement to the submitted manuscript, many of which I think can be easily addressed.</p></disp-quote><p>We thank all reviewers for their valuable feedback on our manuscript and addressed all questions and comments as described in the point-by-point reply. Ca<sup>2+</sup>-binding affinities of EFCaBPs measured in vitro give an estimate of the actual affinity at physiological conditions in a cell. A number of factors including competition with Mg<sup>2+</sup>, target binding and other factors can significantly shift Kd to higher or lower values in the cell. We addressed these points specifically in introduction and discussion as described in detail in response to reviewer #1. We also introduced changes throughout the manuscript to consistently describe different states (Ca<sup>2+</sup>-, Mg<sup>2+</sup>- and apo-state) of the protein as well as its conformations (open, closed and target-bound) based on our biochemical characterization. Details of the updates are provided in responses to reviewers #2 and #3. In response to the numerous detailed suggestions provided by reviewer #2, we have implemented updates that enhanced the manuscript (including Trp spectra).</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>Please address the implications of Ca<sup>2+</sup> binding affinities of the CHP proteins to the physiological concentrations of Ca<sup>2+</sup>.</p></disp-quote><p>Ca<sup>2+</sup>-binding affinities of EFCaBPs measured in vitro give an estimate of the actual affinity at physiological conditions in a cell. A number of factors including competition with Mg<sup>2+</sup>, target binding and others can significantly shift Kd to higher or lower values. This has been discussed in details by Gifford and colleagues (Ref. 18). Indeed, target binding (NHE1 CBD) strongly increased Ca<sup>2+</sup>-binding affinities for CHP1 and CHP2 (Refs 16-17), whereas the presence of Mg<sup>2+</sup> decreased the Ca<sup>2+</sup>-binding affinity of CHP3 to 3.5 µM (Ref 4). Assuming that Mg<sup>2+</sup> would also compete for Ca<sup>2+</sup> binding to CHP1 and CHP2, the respective affinities for Ca<sup>2+</sup> could be above the resting Ca<sup>2+</sup> concentration. At the same time, CHP3 affinity might be impacted by interaction with its target proteins including NHE1, so that the Ca<sup>2+</sup>-binding affinity of the complex could fit to the concentration range of Ca<sup>2+</sup>-signals.</p><p>We added the following information to the introduction:</p><p>“Further, Ca<sup>2+</sup>-binding affinities of CHP1 and CHP2 strongly increased (45-fold and 42-fold, respectively) upon binding of the NHE1 target peptide (16, 17). This modulation is a common feature in EFCaBPs (18) and should also apply to the CHP3 isoform. CHP3 may thus respond to Ca<sup>2+</sup> signals with conformational changes when the intracellular Ca<sup>2+</sup> concentration elevates from 100 nM to 1 µM or higher (19).”</p><p>and updated the discussion as follows:</p><p>“Ca<sup>2+</sup>-induced conformational changes are a hallmark of Ca<sup>2+</sup>-sensing EFCaBPs, which control the interaction with and the function of specific target proteins (54). Our in vitro experiments show that Ca<sup>2+</sup> binding induces conformational changes in CHP3, thus it fulfills this prerequisite to respond to Ca<sup>2+</sup> signals in the cell. Based on the reported affinities of CHP3 for Ca<sup>2+</sup> and Mg<sup>2+</sup> (4), CHP3 should bind Mg<sup>2+</sup> at resting Ca<sup>2+</sup> concentration of about 0.1 µM in the cell (19, 55) and it could bind Ca<sup>2+</sup> when intracellular Ca<sup>2+</sup> concentration rises up to 1 µM during signalling events (55).”</p><disp-quote content-type="editor-comment"><p>Please use submicromolar-free Ca<sup>2+</sup> in all experiments.</p></disp-quote><p>The use of saturating millimolar Ca<sup>2+</sup> concentrations and depletion of Ca<sup>2+</sup> with an excess of EGTA is the commonly used and well-accepted approach to study conformational changes of calcium binding proteins including EFCaBPs (e.g. Zanetti et al. and Krishnakumar (2016); <italic>eLife</italic> 5, DOI: 10.7554/<italic>eLife</italic>.17262; Barret et al. and Marino (2023). Proc Natl Acad Sci U S A 120(15): e2300309120, DOI: 10.1073/pnas.2300309120; Sjogaard-Frich et al. and Pedersen (2021), <italic>eLife</italic> 10, DOI: 10.7554/<italic>eLife</italic>.60889.) We followed this approach, as saturating conditions permit the characterization of uniform conformational states of the protein.</p><disp-quote content-type="editor-comment"><p>Have you considered the effect of the poly His tail of the CBD peptide on binding to CHP3 and ions?</p></disp-quote><p>CBD has naturally three consecutive C-terminal histidine residues which we could exploit for binding properties. We only added 3 more histidine residues, so that a potential interference is minimal.</p><disp-quote content-type="editor-comment"><p>What is the stoichiometry of CBD binding to CHP3?</p></disp-quote><p>The stoichiometry is 1:1. Thank you for pointing this out. We added in the Introduction.</p><p>“We previously demonstrated that CHP3 binds at 1:1 ratio to the CHP-binding region of human NHE1 (CBD) with high affinity in the presence of Mg<sup>2+</sup> (35)”.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Several of the EF-hand calcium-binding proteins are myristoylated and target membranes, and the presence of calcium-binding to induce conformational switches that unleashes a myristoyl chain has been shown in some proteins e.g. recoverin. For others, e.g. NCS1, a lack of a calcium-myristoyl switch seems to be the currently accepted mechanism. The manuscript by Becker and co-workers addresses the important question of how the myristoylated calcium-binding EF-hand protein CHP3 is regulated by ion-binding, and how binding of one of its targets, the sodium exchange NHE1 (or a peptide thereof) impacts membrane binding. The manuscript is very well written, and the data are presented in a logical way. The conclusion of a novel mechanism – a target-dependent myristoyl switch seems largely warranted by the data. There are certain wordings and conclusions that would benefit from a more precise language (or down toning) and some additional controls, and I find the discussion lengthy and repetitive to the introduction and result section and would have wished for a broader discussion putting the data in perspective for the function of NHE1 and other ligand-dependent switches. Addressing the below points would increase the value of the work and the applicability of its finding. In no prioritized order, I suggest the following:</p><p>The model and the title &quot;target-dependent&quot; suggest to me that not all targets may induce the switch and that it depends on which target it is bound to. However, only one target has been investigated. Perhaps the more correct term would be target-binding myristoyl switch. And – on that note, how is this mechanism different from the ligand-dependent myristoyl switch previously described and mentioned by the authors? This is not clear from the discussion.</p></disp-quote><p>We had named this mechanism target-dependent myristoyl switch to match the terms used in a recent review on protein myristoylation (Ref 25). We agree that target-dependent might be perceived as “that not all targets may induce the switch and that it depends on which target it is bound to.” As we want to emphasize that the target binding elicits the response, we now rename the mechanism to target-myristoyl switch, which is also matching the names of calcium-myristoyl switch (the prototype of the switches) and GTP-myristoyl switch. We introduced the change throughout the manuscript including the title.</p><p>“Respective regulatory mechanisms were termed Ca<sup>2+</sup>-myristoyl switch (neuronal calcium sensor proteins) (63, 64), GTP-myristoyl switch (ARF1 GTPase (27)), myristoyl/phosphoserine switch (28, 29), and pH-dependent myristoyl switch (hisactophilin (30)). The myristoyl switch induced by protein-protein interaction described here for CHP3 is a novel mechanism that regulates the association of myristoylated proteins with lipid membranes. We propose to call it “target-myristoyl switch” (Figure 8).”</p><disp-quote content-type="editor-comment"><p>Some of the myristoylated calcium-binding EF-hand proteins do not have a calcium-myristoyl switch, e.g. NCS1 and other, are there any correlation between the number of calcium-bound ions and the type of switch? A more thorough discussion on this part is needed.</p></disp-quote><p>We included the following information in the discussion:</p><p>“This regulatory mechanism is called Ca<sup>2+</sup>-myristoyl switch and was described for a subgroup of neuronal calcium sensor (NCS) proteins (recoverin, hippocalcin, visinin-like proteins, and neurocalcin δ) (63, 64). In other NCSs, the position of the myristoyl moiety is not affected by calcium binding, but it is constantly exposed (NCS1, KChIP1) (31, 33) or hidden inside the protein (GCAP1, GCAP2) (23, 54, 64). So far, there is no apparent correlation between number or position of active EF-hands with the position of the myristoyl moiety in NCS proteins. Even for highly homologous myristoylated NCS proteins with known structures, the location of the myristoyl moiety varies (23). Thus, structural information and models are not sufficient to assign a calcium-myristoyl switch.”</p><disp-quote content-type="editor-comment"><p>The claim that the tryptophan moves from a more hydrophobic into solvent exposure cannot be concluded from the intensities alone. The induced dipole in the excited state interacts with the surroundings through dipole-dipole interactions and thus a wavelength shift is expected from hydrophobic (lower wavelength) to solvent (higher wavelength). Please include these data and show the full spectra.</p></disp-quote><p>We appreciate the suggestion and now included the Trp spectra of CHP3 and mCHP3 in Mg<sup>2+</sup>- and Ca<sup>2+</sup>-bound states as Figure 2—figure supplement 2. The spectra show a fluorescence maximum at ~330 nm for CHP3 and mCHP3 in line with the position of Trp191 in the AlphaFold model. It is located in the target binding pocket at the protein surface with the side chain flanked by other hydrophobic residues (Phe187, Ile 190, Ile194, Ile196). Calcium binding did not induce pronounced spectral shifts, but decreased the fluorescence quantum yield. We updated the respective Results section (p.7) as follows:</p><p>“According to the 3D model of CHP3 predicted with AlphaFold2.0 (42), the single tryptophan residue (Trp191) is located in CHP3´s hydrophobic target-binding pocket at the protein surface (Figure 2C) in line with the measured emission maxima of CHP3 and mCHP3 of ~330 nm (Figure 2—figure supplement 2). Intensity and emission maximum of intrinsic tryptophan fluorescence depend on the local environment of the residue (43, 44). Ca<sup>2+</sup> addition decreased the intrinsic fluorescence of CHP3 (Figure 2B) reflecting conformational changes accompanied with changes in the local environment of Trp191 in the hydrophobic pocket. This is in line with an increase of CHP3 hydrophobicity observed with the FPH assay.”</p><disp-quote content-type="editor-comment"><p>Were the melting curves measured by nanoDSF reversible? If not, these are apparent Tms. Can anything be inferred from the slopes (change in enthalpy) upon unfolding? If the structures are different these should be different too.</p></disp-quote><p>Unfolding of free CHP3 and of CHP3 in complex with NHE1 CBD is not reversible. We changed “Tm” for “apparent Tm” (T<sub>m</sub><sup>app</sup>). We added information in the Materials and methods as follows:</p><p>“Unfolding of proteins analysed was irreversible, thus apparent melting temperatures (T<sub>m</sub><sup>app</sup>) are given. They were determined as an inflection point of the unfolding curves using the PR.ThermControl software (Nanotemper Technologies).”</p><p>Due to irreversibility of unfolding, we would not infer any thermodynamic parameters from the unfolding curves.</p><disp-quote content-type="editor-comment"><p>For typsinolysis, what is the coverage? Are there equally dispersed lysines/arginines across the sequence or are there silent regions not captured by this technique? It may be one reason why the nanoDSF data is not correlating with the stability measurements. However, a more detailed analysis of the gels in the supplement data and in the main figure, reveals additional bands for the mCHP3 around 15kDa (3 bands instead of 2) and below 10kDa (3 bands instead of 2) that are not present in the CHP3. These bands would be relevant to analyze. I disagree with the conclusion that by binding the peptide, there are substantial structural changes, the data can only show a lack of cleavage, which may be caused by coverage by binding, and stabilization by binding (and here it would be good to correlate to the nanoDSF data). The use of the word conformation dynamics is not appropriate, no kinetics have been measured, use instead conformational states.</p></disp-quote><p>We integrated information on lysine/arginine position as Figure 4—figure supplement 1A. Cleavage sites are distributed over the entire sequence of CHP3. We added the following sentence in Results:</p><p>“Trypsin cleavage sites (Arg and Lys residues) are distributed all over the CHP3 sequence (Figure 4—figure supplement 1A), yet productive cleavage requires not only availability of the site but it requires also flexibility of the peptide chain at the cleavage site to adapt to the active site of the protease (45).”</p><p>This update includes addition of reference (Ref 45).</p><p>We agree that there are minor differences in the tryptic cleavage of CHP3 and mCHP3. We updated results as follows:</p><p>“In addition, a second minor band below fragment 1 appeared for mCHP3 (Figure 4B). The small differences in the tryptic cleavage of CHP3 and mCHP3 indicate a local destabilizing effect of the myristoyl moiety, in line with the lower thermal stability of mCHP3 compared to CHP3.”</p><p>Regarding coverage and stabilization by binding: CBD is highly unlikely to inhibit the cleavage by covering the two main cleavage sites, as they are facing away from the hydrophobic target binding pocket. For better visualization, we updated Figure 4D by reorienting the model and adding surface representation to emphasize the relative positions of binding pocket and cleavage sites. Furthermore, the thermal stability of CHP3 is not increased upon CBD binding in presence of Mg<sup>2+</sup>, whereas it increased in the presence of Ca<sup>2+</sup> (figure 3, nanoDSF), while CBD binding increased CHP3 proteolytic stability in both conditions. We updated results as follows: “Both major cleavage sites are highly unlikely to be covered by CBD in the complex, as they are facing away from the target-binding pocket (Figure 4D). Thus, the drastic changes in the proteolytic stability indicate reduced flexibility in EF-2 and EF-4 which could be caused by structural rearrangements of CHP3 upon target peptide binding.</p><p>We agree that we did not include kinetic data and thus the term dynamics might be misleading. Thus, we omitted the term conformational dynamics and now consistently throughout the manuscript including Figure 7 refer to conformation (open or closed) or conformational changes. In addition, we use the term state in context of Mg<sup>2+</sup>- or Ca<sup>2+</sup>-bound state or apo-state.</p><disp-quote content-type="editor-comment"><p>The two-fold difference in affinity between CHP3 and mCHP3 for CBD is small, and thus one could argue that this is insignificant. However, it has a resemblance to some of the works on the disordered flanking regions of folded proteins that dynamically occupy a binding site in the folded domain (see e.g. works on RST and p53 with tails PMID: 34687712 and PMID: 30420502) – similar effect were seen. Would be a good addition to the discussion.</p></disp-quote><p>Thanks for bringing this up. We included in the discussion:</p><p>“As the effect on affinity is small, the myristoyl moiety binds most likely weakly or transiently to the target binding pocket. This resembles the dynamic regulatory interaction of disordered protein regions of p53 to its DNA-binding domain (65) and of Radical-Induced Cell Death 1 (RCD1) to the ligand-binding pocket (66).”</p><p>The suggested publications were added as references 65 and 66.</p><disp-quote content-type="editor-comment"><p>The discussion is lengthy and not forward-looking. The entire first paragraph is mostly a repetition of the introduction.</p></disp-quote><p>The discussion was updated as described in our answers to questions and comments. Further, the redundant part of the first and second paragraph was deleted.</p><disp-quote content-type="editor-comment"><p>It would have been appropriate to include other already mentions points above as well as a reflection of how the other calcium-binding sensitive partners to NHE1 (calmodulin and calcineurin) and the membrane interaction of NHE1 would jointly organize NHE1 at the membrane.</p></disp-quote><p>We included the following sentence in the discussion:</p><p>“This information would be valuable also to elucidate signal integration through the regulatory domain of NHE1, which acts as signaling hub interacting with several regulatory proteins including the ca<sup>2+</sup>-binding proteins calmodulin and calcineurin (3).”</p><disp-quote content-type="editor-comment"><p>In the discussion, it is concluded that Ca<sup>2+</sup> induced higher flexibility. How is this conclusion reached? The same pattern of peptide cleavage is reached, and the protein is destabilized, which could be due to a different conformation as also probed with the hydrophobicity assay. It is not necessarily more flexible. Please elaborate on this to make the argumentation clearer or remove it from the discussion if not fully supported.</p></disp-quote><p>We updated the argumentation in results and discussion omitting the general term flexibility and now distinguishing between thermal stability (nanoDSF) and local flexibility (limited proteolysis). For updates in results, please see paragraph “Ca<sup>2+</sup> binding to CHP3 allows more effective cleavage within EF-2, whereas CBD binding drastically increases proteolytic stability” and related updates in paragraph three of the discussion.</p><disp-quote content-type="editor-comment"><p>Also, in the discussion, it is suggested that the conformation of the N-terminal lobe is affected, which data supports this? How can this be inferred from the presented data? It is also indicated in Figure 7.</p></disp-quote><p>The argumentation is based on the effect of Ca<sup>2+</sup> binding in the C-lobe on the limited trypsinolysis in the N-lobe. We clarified in the discussion as follows:</p><p>“Further, replacement of Mg<sup>2+</sup> with Ca<sup>2+</sup> at EF-3 (C-lobe) lowered the thermal stability of CHP3 and mCHP3 and enhanced proteolytic cleavage in EF-2 (N-lobe) suggesting an increase in local flexibility. Thus, Ca<sup>2+</sup> induced conformational changes involve not only the C-lobe of CHP3 but also its N-lobe.”</p><disp-quote content-type="editor-comment"><p>The change in the amount of CHP3 in the liposome fraction upon CBD binding is very interesting and suggests that the myristoyl group and the CDB act cooperatively. Are there any relevant exposed residues on the exposed side of the bound CDB that can explain this? Lysine residues or hydrophobic residues? It would be good to have an AlphaFold2 structure of the complex to help address this.</p></disp-quote><p>As we had stated in the introduction:</p><p>“Membrane binding via the myristoyl moiety is usually enforced with either a second lipidation site or clusters of positively charged and/or hydrophobic residues (25, 26).”</p><p>We do not have such clusters in the CBD construct used. We also generated the model of CHP3 in complex with CBD using ColabFold (Mirdita et al. and Steinegger 2022, Nat. Methods, 19, 679-682, DOI: 10.1038/s41592-022-01488-1), which is based on AlphaFold2 (Ref. 42) and AlphaFold_multimer_v3. The model of the CHP3:CBD is very similar to published structures of CHP1 and CHP2 in complex with the target peptide. There is only one relevant residue at each end of the CBD peptide we used (residues 525-545), namely R525, and Tyr540, which might interact with a membrane. These single residues are unlikely to substantially contribute to the interaction. Noteworthy, there is a cluster of three lysine residues upstream of the CBD sequence (Lys518, Lys519, Lys520). These residues might further enhance the membrane association of myristoyl-anchored CHP3 in complex with NHE1. This is beyond the scope of the current study.</p><disp-quote content-type="editor-comment"><p>The 3 remaining EF-hands appear not to bind calcium, where are they mutated, and which properties do they then have? Please include.</p></disp-quote><p>EF-2 and EF-4 of CHP3 have 9-residue insertions within the Ca<sup>2+</sup>-coordinating loop, whereas EF-1 lacks conservative negatively charged residues important for Ca<sup>2+</sup> coordination in positions X, Y and –Z. Thus, they still have an EF-hand-like fold, but are unable to bind Ca<sup>2+</sup>. We added this information to the legend of Figure 4—figure supplement 2.</p><disp-quote content-type="editor-comment"><p>Figures</p><p>Figure 1 – it appears for both proteins that a fraction of dimers elutes as well to the left of the main peak. Please comment.</p></disp-quote><p>CHP3 can form an intermolecular disulfide bond in the absence or even at a low concentration of reducing agent. This was previously noted in size exclusion chromatography experiments (Ref. 4). At the very C-terminus, the last but one residue is Cys213, which should be accessible for the reaction. We added to the figure legend of Figure 1, panel C:</p><p>“A shoulder with shorter arrival times indicates the presence of a low abundant dimeric species for CHP3 and mCHP3.”</p><p>At the same time, we did not observe CHP3 dimerization with analytical SEC (Figure 1—figure supplement 1) under reducing conditions.</p><disp-quote content-type="editor-comment"><p>Figure 4 – relevant to indicate the potential coverage (Ks and Rs in the sequence) and not just the two where you see cleavage. Aldo the additional bands on the mCHP3 should be acknowledged.</p></disp-quote><p>We added the potential coverage (K and R residues) of CHP3 in Figure 4—figure supplement 1 as panel A. We mentioned the presence of an additional band for mCHP3 as described in our answer to the question “For trypsinolysis, what is the coverage?”</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>The description of the limited proteolysis experiment would benefit from additional detail. E.g., how many trypsin sites are in CBD? Is the stoichiometry of CBD:CHP3 1:1 or is an excess of CBD added? In the case of the latter, an experiment to determine whether CBD inhibits trypsin may be considered. Admittingly, this is unlikely to be the case, but it would further strengthen the claim of CBD-mediated stabilization.</p></disp-quote><p>The description of the limited proteolysis results was updated for clarity as described in response to reviewer #2 (see answer to question: “For trypsinolysis, what is the coverage?&quot;). Further, there are no trypsin cleavage sites in CBD except the first residue, Arg525. We obtained the CHP3:CBD complex via co-expression in <italic>E. coli</italic> followed by co-purification. Due to formation of the stable complex, no free CBD is present in the reaction mix. The stoichiometry of CBD:CHP3 is 1:1, as previously shown. We updated the corresponding sentence in Introduction:</p><p>“We previously demonstrated that CHP3 binds at 1:1 ratio to the CHP-binding region of human NHE1 (CBD) with high affinity in the presence of Mg<sup>2+</sup> (35).”</p></body></sub-article></article>